On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the pathophysiology as a multi-stage cascade beginning with calcium dysregulation in pancreatic acinar cells. This leads to the premature conversion of trypsinogen to active trypsin, causing cellular autodigestion and the release of damage-associated molecular patterns (DAMPs) that trigger (SIRS).
- •Distinguish between the two clinical phases of the disease: the Early Phase (first week), dominated by the host's systemic inflammatory response and potential early organ failure, and the Late Phase (beyond one week), characterized by local complications such as peripancreatic fluid collections and persistent systemic inflammation.
- •Classify severity using the Revised Atlanta Classification (RAC), which categorizes AP into Mild (no organ failure or complications), Moderately Severe (transient organ failure < 48 hours or local/systemic complications), and Severe (persistent organ failure > 48 hours).
- •Identify the primary etiologies, noting that and biliary sludge account for 40–60% of cases, while alcohol consumption accounts for 20–30%. Metabolic triggers, specifically , become a critical risk when serum levels exceed 1,000 mg/dL (11.3 mmol/L).
- •Recognize the "Enigmatic Triad" of (DKA), hypertriglyceridemia, and acute pancreatitis, where each condition can potentially precipitate the others, complicating the initial diagnostic and metabolic stabilization efforts.
- •Note morphological variants including Interstitial Edematous Pancreatitis (IEP), characterized by diffuse enlargement without necrosis, and Necrotizing Pancreatitis, which involves tissue death of the parenchyma or peripancreatic tissues and carries a higher risk of infection.
Evaluation
- •Suspect acute pancreatitis in any patient presenting with sudden-onset, constant, and severe epigastric pain that often radiates to the back and is described as "boring" or "stabbing." Nausea and vomiting are nearly universal and typically do not relieve the pain.
- •Ask about specific risk factors including alcohol intake, history of symptomatic , recent procedures, and medications such as , , or (gliptins).
- •Examine the patient for signs of SIRS, specifically monitoring for tachycardia (HR > 90 bpm), tachypnea, and fever. Persistent tachycardia over the first 7 days is a strong predictor of mortality and infectious pancreatic necrosis.
- •Perform a thorough abdominal exam to identify guarding or rebound tenderness, which may suggest necrotic collections or an . Look for rare hemorrhagic signs like Cullen’s sign (periumbilical ecchymosis) or Grey Turner’s sign (flank ecchymosis).
- •Order a serum lipase level immediately; a value ≥ 3 times the upper limit of normal is highly suggestive of AP. Note that amylase is less specific and may return to normal more quickly than lipase.
- •Obtain a complete metabolic panel and lipid profile to screen for and assess renal function (creatinine) and liver enzymes (ALT > 150 U/L suggests a biliary etiology).
- •Calculate the Neutrophil-to-Lymphocyte Ratio (NLR) at admission and at 48 hours; a rising or persistently elevated NLR is a low-cost marker for predicting persistent organ failure.
- •Monitor for "Red Flags" indicating the need for ICU escalation, including hypotension unresponsive to initial fluids, altered mental status, or respiratory distress (FVC < 15 mL/kg or rising oxygen requirements).
- •Utilize the Modified Marshall Scoring System to objectively define organ failure across the respiratory (PaO2/FiO2 ratio), renal (serum creatinine), and cardiovascular (systolic blood pressure) systems.
- •Order a contrast-enhanced computed tomography (CECT) scan only if the diagnosis is uncertain or if the patient fails to improve after 48–72 hours, as early imaging may underrepresent the extent of pancreatic necrosis.
- •Screen for on the extensor surfaces of the extremities if hypertriglyceridemic pancreatitis is suspected, and assess for which correlates with worse clinical outcomes.
Management
- •Administer aggressive fluid resuscitation with isotonic crystalloids (Lactated Ringer's is often preferred) at 250–500 mL/h initially, unless cardiovascular or renal contraindications exist. Frequent reassessment of fluid status every 6–12 hours is mandatory to avoid fluid overload.
- •Initiate early enteral nutrition (oral or tube feeding) within 24 hours if tolerated, as it maintains the intestinal barrier and reduces the risk of bacterial translocation and infected necrosis compared to parenteral nutrition.
- •Manage pain aggressively using intravenous opioids (e.g., hydromorphone or fentanyl) or multimodal analgesia; avoid relying solely on NSAIDs in the acute phase due to renal risks.
- •Avoid prophylactic antibiotics in patients with sterile necrosis; antibiotics should be reserved for suspected or confirmed infected necrosis (e.g., new fever, rising WBC, or gas on CT).
- •Administer carbapenems (e.g., Meropenem 1g IV every 8 hours) or quinolones with metronidazole if infected necrosis is confirmed, as these agents have superior pancreatic tissue penetration.
- •Implement the "Step-Up" approach for infected pancreatic necrosis: start with percutaneous or endoscopic ultrasound-guided transluminal drainage (EUS-TD) before considering minimally invasive necrosectomy.
- •Utilize lumen-apposing metal stents (LAMS) for the drainage of walled-off necrosis (WON) to improve drainage efficiency and facilitate early nutritional recovery.
- •Treat severe (TG > 1,000 mg/dL) with an insulin infusion (0.1 units/kg/hour) or plasmapheresis to rapidly lower lipid levels and prevent further acinar injury.
- •Perform a during the same admission for all patients with mild biliary pancreatitis to prevent recurrent attacks; for severe cases, delay surgery until inflammatory collections have stabilized.
- •Monitor Procalcitonin (PCT) levels; a value > 1.0 ng/mL is highly suggestive of pancreatic necrosis and may guide the decision for invasive sampling.
- •Initiate Pancreatic Enzyme Replacement Therapy (PERT) (e.g., Creon 25,000–50,000 units per meal) in patients showing signs of malabsorption or those recovering from necrotizing pancreatitis to manage exocrine insufficiency.
- •Refer patients with persistent organ failure, extensive necrosis, or complex local complications to a tertiary specialized center early (within 24–48 hours) to reduce the risk of progression to SAP.
- •Monitor for pancreatic encephalopathy, characterized by confusion or neurological deficits, which may result from the systemic release of pancreatic enzymes like phospholipase A2.
- •Discharge patients once pain is controlled with oral medications, they can tolerate an oral diet, and systemic inflammatory markers are trending downward. Ensure a follow-up plan for repeat imaging if local collections were present.
Board Review — High Yield
- •Cullen's sign — Periumbilical ecchymosis indicating retroperitoneal hemorrhage/hemorrhagic pancreatitis.
- •Grey Turner's sign — Flank ecchymosis associated with severe necrotizing pancreatitis.
- •Sentinel Loop — A localized ileus of a jejunal loop seen on abdominal X-ray near the inflamed pancreas.
- •Revised Atlanta Classification — Defines severity based on organ failure duration: transient (<48h) vs persistent (>48h).
- •Hypertriglyceridemia — AP risk increases significantly when serum triglycerides exceed 1,000 mg/dL.
- •Step-up approach — The strategy of using percutaneous/endoscopic drainage before surgical necrosectomy for infected necrosis.
- •Pancreatic Encephalopathy — Neurological symptoms caused by circulating pancreatic enzymes and cytokine-mediated neuroinflammation.
- •Iatrogenic triggers — Post-ERCP pancreatitis is a common complication; risk is higher in patients with intrapancreatic fat deposition.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Acute pancreatitis is clinically heterogeneous, ranging from self-limited disease to complicated illness with substantial morbidity and mortality. [106][107]
- ▸The revised Atlanta framework classifies AP as mild, moderately severe, or severe. [106][108]
- ▸Severe AP is defined by persistent organ failure lasting more than 48 hours. [114]
- ▸Post-pancreatectomy acute pancreatitis is a distinct postoperative entity involving symptoms, characteristic CT findings, and sustained postoperative hyperamylasemia for at least 48 hours under the consensus definition. [3][20]
- ▸Biomarkers, scoring systems, imaging models, and phenotypic factors support risk prediction but do not replace outcome-based severity classification. [7][8][9][107][109][110][112][115]
Definition
Acute pancreatitis (AP) is an acute inflammatory disorder of the pancreas with a clinically heterogeneous course, ranging from a self-limited illness to a complication-prone disease associated with substantial morbidity and mortality. Up to approximately one-third of patients may develop complications, supporting classification by clinical severity rather than by symptoms alone. [106] AP is also described as an acute gastrointestinal inflammatory syndrome requiring assessment of both pancreatic injury and systemic consequences. [106][107]
The diagnosis and classification of AP should follow contemporary evidence-based guidance, particularly the revised Atlanta framework, which is used to distinguish mild, moderately severe, and severe disease. [106][108][114] The revised Atlanta classification is clinically outcome-oriented: severe AP is defined by persistent organ failure lasting more than 48 hours, whereas early prediction models attempt to identify patients at risk before this threshold is reached. [114] Non-contrast CT-based artificial-intelligence models have likewise been developed to classify AP as mild, moderately severe, or severe according to the revised Atlanta categories. [108]
Synonyms and related terms
Common synonyms include “acute pancreatitis,” “AP,” and, when persistent organ failure is present, “severe acute pancreatitis” or “SAP.” The term “moderately severe acute pancreatitis” refers to an intermediate category within the revised Atlanta classification, while “mild acute pancreatitis” denotes the least severe category in that framework. [106][108]
“Post-pancreatectomy acute pancreatitis” (PPAP) is a distinct postoperative entity and should not be conflated with ordinary, non-operative AP. The International Study Group for Pancreatic Surgery consensus definition incorporates clinical symptoms, characteristic CT findings, and sustained postoperative hyperamylasemia for at least 48 hours. [3][20]D Studies after distal pancreatectomy have evaluated alternative definitions involving transient postoperative hyperamylasemia lasting less than 48 hours, indicating continuing uncertainty about the most clinically discriminative postoperative criteria. [20]D A systematic review and meta-analysis found that both postoperative hyperamylasemia and PPAP, when defined according to the international consensus, have clinically relevant associations after pancreatectomy. [3]
Classification by severity
| Category | Defining clinical concept | Evidence and qualification |
|---|---|---|
| Mild AP | Mildest revised Atlanta category | Used as a comparator category in contemporary guidelines, imaging models, and observational studies. [106][108] |
| Moderately severe AP | Intermediate revised Atlanta category | Recognized separately from mild and severe disease in current classification and prediction research. [106][108] |
| Severe AP (SAP) | Persistent organ failure for >48 hours | This duration is the reference threshold for the gold-standard classification of severe disease, although it may delay definitive classification. [114] |
| PPAP | Postoperative pancreatitis after pancreatic resection | Requires clinical symptoms, characteristic CT findings, and sustained postoperative hyperamylasemia for ≥48 hours under the consensus definition. [3][20]D |
Severity classification is distinct from risk prediction. Several admission biomarkers and scores—including platelet-to-lymphocyte ratio, neutrophil percentage-to-albumin ratio, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, BISAP, and APACHE II—are being studied to identify patients likely to develop severe disease, but they do not replace the revised Atlanta outcome-based classification. [7][112][115] Oxidative-stress studies also use differing definitions of AP severity, an inconsistency that must be considered when comparing results across studies. [107] In patients with HIV infection, immune dysregulation may affect the performance of inflammatory biomarkers used to estimate severity, further supporting cautious interpretation of surrogate markers. [109]
Etiologic and phenotypic modifiers
Etiology and patient phenotype are clinically important modifiers but are not substitutes for severity classification. Multiple-substance exposure—including combinations of tobacco, alcohol, cannabis, and illicit substances—has been evaluated as a risk factor for AP. [2] Obesity is associated with more severe disease and higher mortality, while sarcopenia and sarcopenic obesity have been investigated in relation to prolonged hospitalization and adverse outcomes. [110][8] Hypertriglyceridemic AP is a recognized etiologic phenotype; studies have assessed triglyceride thresholds and combined early predictors for identifying severe cases, but these parameters do not create a separate universally accepted severity classification. [113][117]
Other proposed prognostic features include admission immune indices, vitamin D status, hyperglycemia, and non-contrast CT findings. [9][19]D[112][114] These findings may refine risk assessment but remain adjunctive to the clinical classification system. Experimental studies of oxidative, neuroimmune, serotonergic, and ferroptosis-related pathways concern mechanisms or potential interventions rather than diagnostic definitions or established clinical categories. [107][111]
Practical terminology
For documentation, the preferred terminology is “acute pancreatitis, mild,” “acute pancreatitis, moderately severe,” or “acute pancreatitis, severe,” with explicit recording of organ failure, local complications, etiology, and—when relevant—postoperative status. [106][108][114] Classification should be reassessed over time because early clinical prediction and later definitive severity assignment are not equivalent: a patient may initially be considered at high risk, whereas severe AP is established by persistent organ failure beyond 48 hours. [114][115]
| Category | Defining clinical concept | Evidence and qualification |\n|---|---|---|\n| Mild AP | Mildest revised Atlanta category | Used in guidelines and contemporary classification studies. [106][108] |\n| Moderately severe AP | Intermediate revised Atlanta category | Distinguished from mild and severe disease in current research. [106][108] |\n| Severe AP | Persistent organ failure for >48 hours | Definitive severity threshold in the revised Atlanta framework. [114] |\n| PPAP | Postoperative pancreatitis after pancreatic resection | Consensus criteria include symptoms, characteristic CT findings, and sustained hyperamylasemia for ≥48 hours. [3][20]D |
Etiology and Triggering Factors
- ▸Hypertriglyceridemia is an increasingly important cause of acute pancreatitis and is associated with a higher proportion of severe disease. [207] [169] [170]
- ▸Familial chylomicronemia syndrome is a rare autosomal-recessive disorder with extreme triglyceride elevation and high lifetime risk of acute pancreatitis. [172]
- ▸A triglyceride threshold of >885 mg/dL was used in one hospital-based study to screen for probable familial chylomicronemia syndrome. [128]
- ▸Tamoxifen-associated hypertriglyceridemia was accompanied by acute pancreatitis in 31 of 49 reported patients, with median triglycerides rising from 274 to 2,534 mg/dL. [208]
- ▸Concurrent propofol and clevidipine infusions may increase lipid-related hypertriglyceridemia risk; one study assessed triglycerides >400 mg/dL and acute pancreatitis after at least 6 hours of coadministration. [171]
- ▸Pegaspargase-associated severe acute pancreatitis with multiple-organ dysfunction was reported 48 hours after infusion in a child with acute lymphoblastic leukemia. [213]
- ▸Choledocholithiasis and gallstone disease are biliary contexts associated with pancreatitis, while ERCP can cause post-ERCP pancreatitis. [214] [212] [129]
- ▸Smoking has been studied as a predictor of recurrence after a first hypertriglyceridemia-induced pancreatitis episode rather than as a confirmed initiating cause. [126]
Overview
Acute pancreatitis (AP) has several etiologic pathways; the updated evidence supplied here particularly supports hypertriglyceridemia-associated acute pancreatitis (HTG-AP), biliary disease, medication-related injury, inherited disorders of triglyceride metabolism, and selected procedure- or disease-associated triggers. Hypertriglyceridemia is described as a major and increasingly frequent cause of AP, and HTG-AP is associated with a greater proportion of severe presentations than many other forms of AP. [207] [169] [170]
Hypertriglyceridemia
Severe hypertriglyceridemia is an important precipitant of AP. Familial chylomicronemia syndrome (FCS), a rare autosomal-recessive disorder of triglyceride metabolism, produces persistent extreme hypertriglyceridemia and carries a high lifetime risk of recurrent AP. [172] Clinical diagnosis scores have been validated against molecularly defined FCS cohorts, supporting the need to distinguish monogenic FCS from non-FCS or multifactorial chylomicronemia in patients with severe hypertriglyceridemia. [172] A hospital-based screening study from Pakistan similarly evaluated probable FCS among individuals with triglycerides above 885 mg/dL, although the available evidence does not establish population prevalence or causality beyond that setting. [128]
Multifactorial metabolic disturbances can also trigger HTG-AP. Poorly controlled type 2 diabetes, insulin resistance, severe dyslipidemia, pancreatic fat infiltration, and an LRP6 variant were described together in a young adult with triglycerides exceeding 37.87 mmol/L; this was a case report and cannot determine the independent contribution of the genetic variant, diabetes, or metabolic derangement. [176]C The clinical importance of HTG extends beyond the initial attack: patients with HTG-AP have a high risk of post-acute pancreatitis diabetes mellitus, consistent with substantial pancreatic and metabolic injury after the acute episode. [173]
The available observational evidence also suggests that the intensity and trajectory of triglyceride exposure may matter. In a cohort of 526 patients with HTG-AP, serial triglyceride measurements during the first 7 days were used to identify clearance trajectories and time-weighted exposure in relation to severe AP and pancreatic necrosis; these findings address prognostic association rather than proof that delayed clearance causes severity. [210] Another retrospective cohort reported that HTG-AP is associated with early severe progression, systemic complications, and mortality, while lipidomic signatures were investigated to improve severity stratification. [170]
Genetic and hematologic predisposition
FCS should be considered when severe hypertriglyceridemia is accompanied by recurrent AP or features suggesting a monogenic disorder, particularly when the clinical phenotype is disproportionate to common secondary factors. [172] [128] Sickle cell disease (SCD) may increase AP burden indirectly through gallstone formation: children with SCD have an increased risk of gallstones, and a multicenter administrative-database study evaluated whether children with SCD hospitalized for AP experienced more readmissions, complications, transfusions, procedures, or longer hospitalization than children without SCD. [211] The available abstract supports SCD as a relevant clinical context but does not establish a direct pancreatic mechanism independent of gallstone disease. [211]
Biliary and procedure-related triggers
Choledocholithiasis is a recognized biliary trigger because obstruction may lead to cholangitis and pancreatitis; a Romanian tertiary-center cohort characterized adults with confirmed choledocholithiasis undergoing endoscopic retrograde cholangiopancreatography (ERCP). [214]C Gallstone pancreatitis remains clinically important in contemporary cohorts evaluating ERCP timing, although the supplied study assessed management outcomes rather than estimating the population fraction attributable to gallstones. [212]C ERCP itself can precipitate post-ERCP pancreatitis (PEP). In a Japanese multicenter cohort, visceral adipose tissue was evaluated as an independent predictor of severe PEP, indicating that patient body composition may modify the severity of this procedure-related complication. [129] [212]C
Drug-induced and treatment-associated pancreatitis
Medication-related hypertriglyceridemia can act as an indirect trigger. A systematic review of tamoxifen-associated hyperlipidemia identified 49 reported patients; triglycerides increased from a median of 274 mg/dL before treatment to 2,534 mg/dL after initiation, and AP occurred in 31 patients (63.3%). Because the evidence consisted of case reports and case series, the findings support clinical vigilance rather than a precise incidence estimate. [208]C
Propofol and clevidipine are both administered as lipid emulsions. A multicenter retrospective study examined adults receiving concurrent infusions for at least 6 hours, focusing on triglycerides above 400 mg/dL and AP, because combined lipid exposure may increase the risk of hypertriglyceridemia and potentially pancreatitis. [171]C The study evaluates association and risk factors, not definitive causation. Pegaspargase is another clinically important drug trigger: a pediatric case described severe AP with multiple-organ dysfunction developing 48 hours after pegaspargase infusion during treatment for B-cell precursor acute lymphoblastic leukemia. [213] This report demonstrates temporal association in an individual patient and does not establish the frequency of pegaspargase-induced AP.
Behavioral and contextual factors
Smoking is relevant primarily to recurrence after an HTG-AP episode rather than as a proven initiating cause in the supplied evidence. A multicenter retrospective cohort specifically examined baseline current smoking and time-varying recurrence risk after a first HTG-AP episode, indicating that smoking status may influence subsequent disease burden. [126] The study design supports association with recurrence but cannot by itself prove that smoking caused the initial pancreatitis.
Evidence boundaries
Several supplied studies concern treatment, severity prediction, or laboratory response rather than etiology. Meta-analyses evaluated intensified insulin therapy and plasmapheresis for established HTG-AP, while a real-world study described laboratory changes after blood purification without inferring causal efficacy. [207] [169] [209] These studies reinforce the clinical importance of HTG-AP but should not be interpreted as evidence that insulin, plasmapheresis, or blood purification prevents the initiating trigger.
| Context | Evidence and qualification |
|---|---|
| Hypertriglyceridemia | Major and increasingly frequent cause; associated with severe progression and complications. [207] [170] |
| Familial chylomicronemia syndrome | Monogenic triglyceride-metabolism disorder with high lifetime AP risk. [172] |
| Diabetes and insulin resistance | Severe metabolic dysregulation may promote extreme hypertriglyceridemia and HTG-AP. [176]C |
| Biliary obstruction | Choledocholithiasis and gallstone disease are associated with pancreatitis. [214]C [212]C |
| ERCP | Procedure-related trigger of post-ERCP pancreatitis; visceral adiposity may predict severity. [129] |
| Tamoxifen | Reported to cause marked hypertriglyceridemia; AP occurred in 63.3% of reviewed reports. [208]C |
| Propofol plus clevidipine | Concurrent lipid-emulsion infusions may increase hypertriglyceridemia risk. [171]C |
| Pegaspargase | Temporally associated with severe AP and multiple-organ dysfunction in a pediatric case. [213] |
| Sickle cell disease | May increase AP burden through increased gallstone risk; direct causation is not established. [211] |
Pathophysiology
- ▸AP involves pancreatic injury followed by innate-immune activation, cytokine amplification, and possible systemic organ dysfunction. [182]
- ▸IL-1β, IL-6, and TNF-α may amplify inflammation, whereas IL-10 may provide counter-regulation. [182]
- ▸Gut dysbiosis and intestinal-barrier dysfunction are important emerging hypotheses, but the supplied evidence does not prove causality. [140]
- ▸Hypertriglyceridemia, insulin-resistance signals, alcohol-related hepatic injury, and reduced nutritional or muscular reserve may modify severity. [170][183][219][148]
- ▸miR-215-5p–mediated SLC7A11 suppression and ferroptosis are experimental mechanisms of acinar-cell injury. [220]
- ▸Inflammatory indices and cytokine concentrations are mainly severity or risk correlates, not definitive mechanistic biomarkers. [127][144][215][216][217]
Initiating pancreatic injury
Acute pancreatitis (AP) is an acute inflammatory syndrome in which pancreatic injury is followed by activation of innate immunity, amplification of inflammatory signalling, intestinal barrier disturbance, and, in severe disease, systemic inflammation with organ dysfunction. The supplied evidence describes AP as involving intense mediator release and rapid recruitment and activation of innate immune cells, with increased circulating IL-1α, IL-1β, IL-6, IL-10, and additional cytokines in affected patients. [182] The balance between pro-inflammatory mediators, including IL-1β, IL-6, and TNF-α, and counter-regulatory mediators such as IL-10 may influence whether inflammation remains locally confined or progresses systemically. [182]
Several etiologic contexts can intensify this process. Hypertriglyceridemic pancreatitis is associated with a higher risk of early severe progression, systemic complications, and mortality than AP from other causes; lipidomic and clinical modelling studies therefore support a contribution from disordered lipid metabolism to disease severity. [170] A composite C-reactive-protein–triglyceride–glucose index was specifically developed to integrate inflammation and insulin-resistance signals in AP, supporting an interaction between inflammatory and metabolic pathways, although the cited study is observational and does not establish causality. [219] Alcohol-related pancreatitis may be accompanied by alcohol-related hepatitis, in which combined hepatic and pancreatic injury is associated with greater systemic inflammation and organ dysfunction. [183] Acute pancreatitis can also occur as an adverse effect of pegaspargase, and a reported pediatric case involved severe AP with persistent multiple-organ dysfunction after treatment. [213]
Immune amplification and systemic inflammation
Once pancreatic inflammation is established, circulating inflammatory-cell and acute-phase responses provide indirect evidence of the underlying biology. Studies of admission indices use neutrophil, lymphocyte, platelet, C-reactive protein, albumin, creatinine, and nutritional variables to quantify systemic inflammation, immune status, and early organ dysfunction. [215][216][217][144] Higher neutrophil-to-lymphocyte ratio was associated with acute liver injury complicating AP in a retrospective cohort, consistent with a relationship between heightened systemic inflammation and extra-pancreatic organ injury; however, this association does not prove that the ratio itself causes liver damage. [127] The neutrophil-creatinine index similarly combines neutrophil activation with impaired renal function as an early marker of severe AP, reflecting the coupled processes of systemic inflammation and organ dysfunction. [144]
The systemic response may progress to systemic inflammatory response syndrome and multiple-organ dysfunction. Severe AP is described as triggering systemic inflammation that can progress to multiorgan dysfunction, with inflammatory markers improving after extracorporeal hemoperfusion followed by hemodiafiltration in one retrospective study; the intervention findings do not establish that circulating mediators are the sole drivers of injury. [178] A case of pegaspargase-associated AP illustrates that persistent inflammatory and organ-failure physiology can occur despite intensive supportive care, whereas therapeutic plasma exchange is not recommended routinely for all patients with AP. [213]
Gut–pancreas interaction
Gut dysbiosis is an increasingly studied component of AP pathophysiology. The research literature identifies possible links between altered gut microbial communities, pancreatic inflammation, intestinal-barrier dysfunction, and disease progression, but the bibliometric evidence maps the research landscape rather than proving a causal microbial pathway. [140] Breakdown of the intestinal barrier could facilitate translocation of microbial products and intensify innate immune activation, but this mechanistic sequence is not directly demonstrated by the supplied bibliometric study. [140]
Cellular injury and regulated cell death
Oxidative and regulated-cell-death pathways may contribute to pancreatic acinar-cell injury. In a clinical and experimental study, miR-215-5p was investigated in AP; experiments in caerulein-injured AR42J acinar cells linked increased miR-215-5p to suppression of SLC7A11, oxidative stress, cellular injury, and ferroptosis. [220] These findings support a model in which microRNA-mediated impairment of antioxidant defence can enhance acinar-cell damage, although the translational significance of the experimental pathway remains uncertain. [220]
Metabolic, nutritional, and reserve-related modifiers
The severity of AP is also shaped by metabolic reserve and the host’s capacity to tolerate inflammation. Sarcopenia, quantified by the psoas muscle index on admission CT, was evaluated as a marker of reduced physiological and nutritional reserve and was associated with progression to moderately severe or severe AP in a multicenter retrospective cohort. [148] Immunonutritional indices such as the prognostic nutritional index, hemoglobin–albumin–lymphocyte–platelet index, and related composite scores are being evaluated because inflammation and malnutrition may interact during AP; their prognostic performance remains cohort-dependent. [215] Admission SII, SIRI, AISI, and multiple inflammatory indices were likewise studied as accessible correlates of severe AP, but these biomarkers describe risk and inflammatory state rather than define the initiating mechanism. [216][217]
Context and limits of current evidence
The supplied studies largely identify associations, biomarkers, or experimental pathways rather than a single linear mechanism. Pediatric AP associated with inflammatory bowel disease remained idiopathic after exclusion of drug, metabolic, infectious, genetic, and structural causes, illustrating that clinically apparent AP may arise without an identified trigger. [181]C Cytokine profiling distinguishes AP from healthy controls, but single-time-point sampling cannot determine temporal causality. [182] Pediatric immune-protein profiling also found that TRANCE, TWEAK, FLT-1, HGF, and TRAIL were increased in chronic pancreatitis compared with AP and healthy controls, suggesting that immune signatures differ between acute and chronic disease rather than defining the acute initiating event. [179] Studies of low butyrylcholinesterase activity in dogs and semaglutide-associated anti-inflammatory or metabolic effects in obesity are not direct evidence of human AP pathogenesis. [218][142] Similarly, studies of acute cholangitis surgery and rare neurologic complications provide clinical context but do not establish mechanisms of AP. [180][184]C
| Domain | Evidence and interpretation |
|---|---|
| Cytokine signalling | Increased pro-inflammatory and regulatory cytokines support immune amplification. [182] |
| Systemic inflammation | Neutrophil-, platelet-, CRP-, and creatinine-based indices correlate with severe disease or organ injury. [127][144][216][217] |
| Gut–pancreas axis | Dysbiosis and barrier dysfunction are prominent research hypotheses, but causal evidence is limited in the supplied source. [140] |
| Metabolic injury | Hypertriglyceridemia and insulin-resistance signals are associated with severe progression. [170][219] |
| Cell death | miR-215-5p/SLC7A11 signalling was linked experimentally to oxidative stress and ferroptosis. [220] |
| Host reserve | Sarcopenia and immunonutritional status may modify progression and outcomes. [148][215] |
History and Physical Examination
- ▸Pain is often the presenting symptom of acute pancreatitis and has prognostic importance; assess and reassess it systematically. [156]
- ▸Pain severity may be discordant with structural disease, especially in recurrent acute or chronic pancreatitis. [161]
- ▸Admission fever has been associated with disease severity and mortality in a systematic review and meta-analysis, but must be interpreted with the complete clinical assessment. [141]
- ▸Ask about recent ERCP or other biliary procedures because postprocedural pancreatitis is a recognized adverse event after ERCP. [72]
- ▸Assess older adults for frailty, comorbidity, functional status, organ dysfunction, and local complications. [168]
- ▸In children, investigate recurrent episodes, systemic disease, medications, trauma, metabolic disorders, and family or genetic history; pediatric diagnosis may follow INSPPIRE criteria. [185]
- ▸In asparaginase-treated children, severe hypertriglyceridemia is defined in the cited study as triglycerides **>1,000 mg/dL**. [167]
- ▸Hyperamylasemia in inflammatory bowel disease is not synonymous with acute pancreatitis. [160]
- ▸Assess nutritional status, recent weight loss, mobility, and sarcopenia risk, particularly in moderately severe or severe disease. [186]
- ▸Confirm pregnancy and gestational age because maternal and fetal outcomes may be affected by AP severity. [187]
Presenting symptoms and pain
Pain is commonly the presenting symptom of acute pancreatitis (AP) and may have prognostic significance; inadequate pain control may adversely affect outcomes. [156] Characterize onset, location, radiation, severity, duration, progression, and response to analgesics, and document pain repeatedly rather than relying only on the initial assessment. [156] Pain intensity may not parallel structural pancreatic abnormalities, particularly in recurrent acute or chronic pancreatitis, because altered peripheral and central pain processing can contribute to symptom severity. [161]C In hospitalized adults, higher serum lipase was associated with receiving analgesics, although this finding came from a single-center retrospective study and should not be used to estimate pain severity in an individual patient. [162]
Ask about previous episodes of AP, recurrent attacks, chronic abdominal pain, and established chronic pancreatitis, because recurrent acute and chronic pancreatitis may have distinct pain-processing phenotypes. [161]C Enquire about recent endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound-guided procedures, or other biliary interventions: postprocedural pancreatitis is a recognized adverse event after ERCP, whereas a randomized trial in malignant distal biliary obstruction evaluated EUS-guided choledochoduodenostomy as an alternative strategy intended to reduce this risk. [72]
Associated symptoms and severity clues
Record nausea, vomiting, inability to tolerate oral intake, abdominal distension, fever or chills, jaundice, dark urine, pale stools, dyspnea, confusion, reduced urine output, weakness, and bleeding symptoms. These symptoms should be interpreted with vital signs and serial examination rather than used in isolation to grade severity. [168] Fever at hospital admission has been specifically studied as a prognostic marker; a systematic review and meta-analysis evaluated its association with mortality and disease-severity markers in adults with AP. [141]
Measure temperature, heart rate, blood pressure, respiratory rate, oxygen saturation, mental status, and urine output at presentation and during reassessment. [141] Examine for dehydration or hypoperfusion, respiratory distress, altered mentation, jaundice, and peripheral edema, and assess the abdomen for distension, bowel-sound abnormalities, epigastric or diffuse tenderness, guarding, and rebound tenderness. [168] Older adults may have greater vulnerability and worse outcomes related to baseline frailty, acute organ dysfunction, and local complications; therefore, document functional status, comorbidity burden, and pre-illness independence. [168]
Etiologic and risk-factor history
Ask specifically about gallstone disease, prior biliary obstruction or cholangitis, alcohol exposure, hypertriglyceridemia, metabolic disease, abdominal trauma, recent procedures, and potentially causative medications or systemic illnesses. The available contemporary pediatric cohort found AP and acute recurrent pancreatitis across a heterogeneous etiologic spectrum and assessed early clinical predictors of severity using the 2017 NASPGHAN classification. [185]
In children and adolescents, obtain a detailed history of recurrent episodes, family history, genetic disease, medication exposure, trauma, infection, and systemic inflammatory or metabolic disorders; pediatric diagnosis in the cited cohort followed INSPPIRE criteria. [185] In children receiving asparaginase for acute lymphoblastic leukemia, ask about recent treatment and lipid abnormalities because severe asparaginase-associated hypertriglyceridemia—defined in the cited study as triglycerides >1,000 mg/dL—was documented as a recognized metabolic complication. [167]C
In patients with inflammatory bowel disease, an elevated amylase does not necessarily establish AP: hyperamylasemia occurred in a pediatric IBD cohort and had multiple possible causes, including factors examined through amylase-gene copy-number analysis. [160]C Interpret amylase and lipase results alongside compatible symptoms and examination findings. [160]C
Nutritional, functional, and special-population assessment
Document recent weight change, appetite, oral intake, vomiting, diarrhea, alcohol-related caloric intake, baseline body mass index, and evidence of malnutrition. Patients with moderately severe or severe AP may develop short-term loss of muscle mass and sarcopenia; assessment may include functional history, handgrip strength, and, when available, computed-tomography-derived skeletal muscle measurements. [186] Ask about pre-existing frailty and mobility limitations, particularly in patients likely to require intensive care, because prolonged immobilization in severe AP is associated with physical deconditioning and has been targeted by structured early rehabilitation programs. [139]
Confirm pregnancy status in patients who could be pregnant and establish gestational age, because AP during pregnancy may affect both maternal and fetal outcomes and severity is clinically important. [187] In pregnancy, document abdominal pain, vomiting, fever, jaundice, and reduced fetal movement when applicable, while coordinating maternal assessment with obstetric evaluation. [187]
Focused examination summary
The initial examination should integrate pain severity, abdominal findings, temperature, hemodynamic stability, respiratory status, mental status, hydration, jaundice, and functional or nutritional reserve. [141][168][186] Repeat the history and examination when pain, fever, hypotension, hypoxemia, oliguria, confusion, or abdominal findings evolve, because AP outcomes reflect the interaction of baseline vulnerability, organ dysfunction, and local complications rather than a single presenting symptom. [168]
| Domain | What to assess | Evidence |
|---|---|---|
| Pain | Onset, location, radiation, severity, trajectory, analgesic response, recurrent or chronic pattern | [156][161]C[162] |
| Systemic severity | Fever, hemodynamics, respiratory status, mental status, urine output, hydration | [141][168] |
| Abdominal examination | Distension, bowel sounds, tenderness, guarding, rebound, jaundice | [168] |
| Etiology and triggers | Biliary disease, alcohol, hypertriglyceridemia, procedures, medications, trauma, systemic disease | [72][160]C[167]C[185] |
| Nutrition and function | Weight change, intake, frailty, mobility, handgrip strength, sarcopenia risk | [139][186] |
| Special populations | Pediatric recurrent disease, pregnancy, recent asparaginase exposure, inflammatory bowel disease | [160]C[167]C[185][187] |
Supportive Care and Complication Management
- ▸Prioritize enteral nutrition when feasible; evidence includes pediatric trials and an adult observational comparison of feeding within **≤48 hours** versus delayed nutrition.[221][150]
- ▸Interpret hypertriglyceridemia using phenotype, serial triglyceride clearance over the first **7 days**, and overall clinical trajectory rather than a single value.[194][210]
- ▸Use procalcitonin and early D-dimer-based risk models only as adjuncts in assessing infected pancreatic necrosis; neither replaces clinical evaluation and imaging.[222][196]
- ▸Manage symptomatic walled-off pancreatic necrosis through multidisciplinary, anatomy- and course-based pathways.[191]
- ▸Individualize anticoagulation for pancreatitis-associated splanchnic vein thrombosis, particularly when portomesenteric thrombosis and bleeding risk coexist.[199]
Nutrition and gastrointestinal support
Early enteral nutrition (EEN) remains a major supportive-care strategy, with the available updated evidence extending specifically to children. A 2026 systematic review and meta-analysis included 9 trials involving 485 children with acute pancreatitis and found significant overall improvement with EEN compared with control interventions, although the abstract does not provide the individual effect estimates or specify which outcomes drove the pooled benefit.[221] A separate retrospective study of 1,600 adults compared enteral nutrition initiated within ≤48 hours with delayed feeding and examined nutritional status, metabolic and inflammatory biomarkers, gut-barrier markers, disease severity, organ failure, and mortality after adjustment for age, sex, body-mass index, etiology, and comorbidities.[150] These findings support prioritizing early nutritional assessment and enteral feeding when clinically feasible, while recognizing that the cited adult study is observational.[150]
Microbiota-directed treatment should not be considered routine replacement for nutritional and organ-supportive care. A 2026 systematic review and meta-analysis evaluated prebiotics, probiotics, and synbiotics against placebo, standard care, or nutritional controls, assessing recovery-related, efficacy, and safety-critical outcomes.[224] Because the provided evidence summary does not report definitive pooled benefits or harms, these interventions should be regarded as investigational or selectively adjunctive rather than standard therapy.[224]
Hypertriglyceridemia-associated acute pancreatitis
Hypertriglyceridemic acute pancreatitis (HTG-AP) is heterogeneous, and treatment response may differ between clinically defined subphenotypes. A prospective cohort of 1,483 patients used latent-class analysis of admission clinical and laboratory variables; the resulting subphenotypes were validated in a multicenter randomized trial of 533 patients evaluating differential responses to low-molecular-weight heparin (LMWH).[194] This evidence supports phenotype-aware interpretation of LMWH effects rather than assuming uniform benefit across HTG-AP.[194] Serial triglyceride monitoring may add prognostic information: a retrospective cohort of 526 patients evaluated triglyceride-clearance trajectories and time-weighted mean triglyceride exposure during the first 7 days after admission in relation to severe disease and pancreatic necrosis.[210] These trajectory-based measures are prognostic associations, not validated treatment targets.[210]
An additional retrospective study of 286 patients with hyperlipidemic acute pancreatitis, including a separate time-validation group of 62 patients, examined peak D-dimer within 24 hours of admission and developed an early risk-stratification model for infected pancreatic necrosis.[196] D-dimer-based prediction should therefore complement, rather than replace, clinical assessment, serial laboratory testing, and imaging.[196]
Necrosis, infection, and walled-off pancreatic necrosis
Procalcitonin has been evaluated specifically for diagnosing infected pancreatic necrosis (IPN) in a systematic review and meta-analysis, with prediction of severe acute pancreatitis assessed as a secondary endpoint.[222] It may assist diagnostic assessment, but biomarker results should be integrated with clinical deterioration, imaging, and microbiological information because the cited abstract does not establish a standalone diagnostic threshold.[222] Sequencing-based studies summarized in another systematic review indicate that pancreatitis-associated intra-abdominal infection, particularly IPN, has a measurable pancreatic microbial composition and diversity; the clinical significance of these microbiota patterns remains an evolving field rather than a basis for routine pathogen-directed therapy.[223]
For symptomatic walled-off pancreatic necrosis (WOPN), the 2026 SAGES clinical practice guideline used a systematic review of evidence published from 1 January 2020 through 24 January 2025 and multidisciplinary GRADE-based consensus involving surgeons, gastroenterologists, and interventional radiologists from SAGES and AHPBA.[191] Management should therefore be individualized within a multidisciplinary pathway, with intervention decisions guided by symptoms, infection, clinical course, anatomy, and local expertise.[191] Retrospective data on 107 patients with IPN after failed conservative therapy and percutaneous drainage compared robot-assisted pancreatic necrosectomy, conventional minimally invasive surgery, and open necrosectomy; robot-assisted procedures had longer operative times than conventional minimally invasive surgery and open surgery, while the study was nonrandomized.[197]
Vascular and intra-abdominal complications
Pancreatitis-associated splanchnic vein thrombosis requires individualized anticoagulation decisions. In a retrospective cohort of 529 patients with necrotizing pancreatitis, 73 patients (13.8%) developed splanchnic vein thrombosis; portomesenteric thrombosis was associated with greater anticoagulant use and more bleeding interventions than isolated splenic-vein thrombosis.[199] Anticoagulation should therefore account for thrombus location, progression risk, recanalization potential, bleeding risk, and the need for invasive procedures.[199]
Automated CT volumetry of peripancreatic collections was developed and externally tested in a multicenter retrospective study of 394 patients, including development, internal-test, and external-test cohorts, to support early risk stratification.[198] It is a promising prognostic tool, but it should not replace expert radiologic interpretation or clinical assessment.[198] A small retrospective study of severe acute pancreatitis evaluated mirabilite external dressing with abdominal drainage, mirabilite alone, or drainage alone; the combined group showed faster abdominal-pain relief and earlier passage of flatus despite baseline differences, so the intervention remains insufficiently established for routine care.[201]
Adjacent evidence and therapies not established for routine AP support
Xuesaitong injection has been studied as an off-label adjunct in China in a randomized-trial meta-analysis, but its efficacy and safety remain uncertain.[192] Cytokine profiling demonstrates inflammatory and counter-regulatory immune activation in AP, including increases in IL-1α, IL-1β, IL-6, and IL-10, but this observational biology does not establish cytokine-directed treatment.[182] Evidence concerning EUS-guided hepaticogastrostomy applies to malignant biliary obstruction rather than AP.[125] Studies of postoperative hyperamylasemia concern post-pancreatectomy pancreatitis,[225] GLP-1 receptor agonists concern pancreatic outcomes in type 2 diabetes,[226] preoperative biliary drainage concerns perihilar cholangiocarcinoma,[227] and a report of squamous metaplasia concerns a diagnostic mimic of malignancy.[202] These findings should not be extrapolated as routine supportive-care recommendations for spontaneous acute pancreatitis.
| Clinical issue | Evidence-informed approach | Evidence limitations |
|---|---|---|
| Nutrition | Favor feasible early enteral nutrition; pediatric evidence includes 9 trials/485 children, and adult observational evidence evaluates feeding within ≤48 h.[221][150] | Adult evidence cited here is observational; pediatric pooled outcome details are not provided in the abstract.[150][221] |
| HTG-AP | Consider subphenotypes and serial triglyceride trajectories over the first 7 days.[194][210] | LMWH effects may differ by phenotype; trajectory measures are prognostic associations.[194][210] |
| IPN | Integrate procalcitonin, D-dimer risk assessment, clinical course, and imaging.[222][196] | No standalone diagnostic threshold is established in the supplied evidence.[222] |
| WOPN/IPN | Use multidisciplinary stepwise assessment and select drainage or necrosectomy according to symptoms, infection, anatomy, and expertise.[191][197] | Necrosectomy comparisons are retrospective and nonrandomized.[197] |
| Splanchnic thrombosis | Balance anticoagulation against thrombus location, progression, recanalization, bleeding, and procedures.[199] | Evidence is retrospective.[199] |
References
- [1]
Vujasinovic M, Demir IE, Marchegiani G et al.. “International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.” United European gastroenterology journal (2026). PMID: 41689768 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification - [2]
Adeniran EA, Jiang Y, Yadav D et al.. “Multiple substance use and the risk of pancreatitis: a systematic review.” Therapeutic advances in gastroenterology (2025). PMID: 40873658 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Heo D, Cardoso SA, Cardoso RP et al.. “Clinical implications of postoperative hyperamylasemia and postpancreatectomy acute pancreatitis after pancreatectomy: A systematic review and meta-analysis.” Surgery (2025). PMID: 40435914 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Kowal MR, Bhatnagar V, Pine J et al.. “Systematic review of peritoneal lavage and dialysis for patients with severe acute pancreatitis.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 39939210 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Williamson L, Hao Y, Basnayake C et al.. “Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus.” Seminars in arthritis and rheumatism (2024). PMID: 39461088 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Haseef M, Li SCH, Gaitt T et al.. “Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.” Current opinion in endocrinology, diabetes, and obesity (2026). PMID: 41717773 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [7]
Ibrahim MY, Alhaj MM, Ibrahim AAA et al.. “Association of platelet-lymphocyte ratio with acute pancreatitis severity: systematic review and meta-analysis.” BMC gastroenterology (2025). PMID: 41388444 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [8]
Kuzman M, Joseph N, Nafady R et al.. “Clinical Impact of Sarcopenia and Sarcopenic Obesity in Acute Pancreatitis: A Systematic Review.” ANZ journal of surgery (2026). PMID: 41351308 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification, History and Physical Examination - [9]
Siuka D, Rakuša M, Vodenik A et al.. “Free and Bioavailable Vitamin D Are Correlated with Disease Severity in Acute Pancreatitis: A Single-Center, Prospective Study.” International journal of molecular sciences (2025). PMID: 40565159 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [10]
Yahia Y, Abuodeh J, Chandra P et al.. “Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study.” Obesity surgery (2025). PMID: 39806256 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [11]
Blažević N, Trkulja V, Rogić D et al.. “YKL-40 as a risk stratification marker in acute pancreatitis: A prospective study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 39638701 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [12]
Guilabert L, Cárdenas-Jaén K, Vaillo-Rocamora A et al.. “Normal saline versus lactated Ringer's solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial study protocol.” Trials (2024). PMID: 39434191 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification - [13]
Grudzińska E, Gajda M. “Postoperative Acute Pancreatitis After Pancreatic Resections-A Narrative Review and a Diagnostic Algorithm.” Cancers (2025). PMID: 40940873 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Sato A, Tani A, Mishima Y et al.. “Assessment of two different criteria for post-pancreatectomy acute pancreatitis: a single-center retrospective analysis and literature review.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 40340215 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Bouça-Machado T, Araújo Teixeira JP, Rebelo P et al.. “Comparison of acute pancreatitis and acute on chronic pancreatitis: a retrospective cohort study.” European journal of gastroenterology & hepatology (2025). PMID: 39976002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [16]
Ranjan MK, Neupane P, Maharjan B et al.. “Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real-World Cohort Study.” Gastroenterology research and practice (2026). PMID: 41971243 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [17]
Zhou H, Li W, Yang S et al.. “Prediction of acute pancreatitis severity using NLR, procalcitonin, and CT severity score: A retrospective study.” Medicine (2025). PMID: 40629608 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [18]
Orbelian L, Trembach N, Durleshter V. “The Role of Inflammatory and Hemostatic Markers in the Prediction of Severe Acute Pancreatitis: An Observational Cohort Study.” Recent advances in inflammation & allergy drug discovery (2025). PMID: 39694959 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [19]
Dungan KM, Chinchilli VM, Pichardo-Lowden A et al.. “Hyperglycemia During Acute Pancreatitis and Progression to Early-Onset Diabetes After Recovery: Preliminary Findings From the Diabetes Related to Acute Pancreatitis and Its Mechanisms (DREAM) Study.” Diabetes care (2026). PMID: 41940812 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Poelsler LH, Bellotti R, Pably D et al.. “Analysis of Different Post-Operative Hyperamylasemia Criteria for Defining Post-Pancreatectomy Acute Pancreatitis After Distal Pancreatectomy-A Retrospective Single-Center Study.” Journal of clinical medicine (2026). PMID: 41827220 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Emara A, Mansour A, Aboeldahab H et al.. “Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41943994 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [22]
Elbahloul MA, Gamal A, Maihoub O et al.. “Efficacy and Safety of Apolipoprotein C-III Inhibitors in Hypertriglyceridemia: A Network Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41917770 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [23]
Rehman A, Rajdeep D, Mohnkern JD et al.. “Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Digestive diseases and sciences (2026). PMID: 41865223 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [24]
Peterson AL, Ashraf AP, Bachman J et al.. “Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41705332 ↗
L1cGUIDELINECited in: Etiology and Triggering Factors - [25]
Masood A, Qureshi AUH, Khalid Z et al.. “Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.” Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace (2026). PMID: 41755797 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [26]
Loomba R, de-Madaria E, Afghani E et al.. “Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study.” Alimentary pharmacology & therapeutics (2026). PMID: 41923352 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [27]
Qi S, Wang S, Chen W et al.. “Clinical outcomes of lipid apheresis in hypertriglyceridemia-induced acute pancreatitis: A 10-year triglyceride-stratified retrospective study.” Journal of clinical lipidology (2026). PMID: 41963121 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [28]
Cerbino B, Süffert LC, Monteiro A et al.. “Intrapancreatic Fat Deposition and Risk of Post-ERCP Pancreatitis: A Systematic Review and Meta-analysis.” Pancreas (2026). PMID: 41668341 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [29]
Shi B, Feng J, Hu P et al.. “Clinical Outcomes and Safety of Ureteral Catheter-Assisted Antegrade Guidewire Intubation in the Laparoscopic-Endoscopic Rendezvous Procedure for Cholelithiasis with Choledocholithiasis: A Retrospective Cohort Study.” Therapeutics and clinical risk management (2026). PMID: 41859199 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [30]
Liu J, Xu H, Huang C et al.. “Admission HDL-C and recurrence risk of hypertriglyceridemia-induced acute pancreatitis: a multicenter cohort study.” Frontiers in nutrition (2026). PMID: 41693951 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [31]
Dayan-Rosenman D, Diletti-Swenson S, Ghayalod N et al.. “Iatrogenic physiologic opioid dependence masquerading as recurrent acute pancreatitis flares: case series.” Addiction science & clinical practice (2026). PMID: 41680940 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [32]
Maringhini A, Patti R, Maringhini M et al.. “Ursodeoxycholic Acid for the Prevention of Relapse of Pregnancy-Related Acute Gallstone Pancreatitis.” Journal of clinical medicine (2026). PMID: 41976880 ↗
L5OTHERCited in: Etiology and Triggering Factors - [33]
Deng F, Ding L, Du YY et al.. “Low-molecular-weight heparin and respiratory failure in hypertriglyceridemia-associated acute pancreatitis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41968002 ↗
L5OTHERCited in: Etiology and Triggering Factors - [34]
Li Y, Wang Y, Wan X et al.. “Radiomics derived from MRI T2-weighted imaging combined with clinical variables for predicting disease severity in hypertriglyceridemic acute pancreatitis.” Abdominal radiology (New York) (2026). PMID: 41925844 ↗
L5OTHERCited in: Etiology and Triggering Factors - [35]
Sirtl S, Ahmad M, Allawadhi P et al.. “NLRP3 Inflammasome Activation-Induced Acute Papillitis as a Trigger of Acute Pancreatitis - A Novel Mechanism of Microlithiasis-Induced Acute Pancreatitis.” United European gastroenterology journal (2026). PMID: 41830600 ↗
L5OTHERCited in: Etiology and Triggering Factors - [36]
Ozkaya M, Atik I, Ozkaya S et al.. “Incidence and clinical significance of biliary and pancreatic duct variations on magnetic resonance cholangiopancreatography.” Abdominal radiology (New York) (2026). PMID: 41801378 ↗
L5OTHERCited in: Etiology and Triggering Factors - [37]
Faraci S, Rollo G, Alghisi F et al.. “ERCP-based management of pediatric chronic pancreatitis: Results from a retrospective long-term multicentric study.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41723027 ↗
L5OTHERCited in: Etiology and Triggering Factors - [38]
Liu Z, He Y, Chen Z et al.. “Pleural effusion within 24 h of admission predicts severe hypertriglyceridemia-induced acute pancreatitis and organ failure: retrospective cohort of 296 patients.” Frontiers in medicine (2026). PMID: 41658612 ↗
L5OTHERCited in: Etiology and Triggering Factors - [39]
Peng Q, Long Y, Yang K et al.. “Prognostic analysis of acute pancreatitis due to different etiologies and establishment and validation of an early prediction model.” Lipids in health and disease (2026). PMID: 41645226 ↗
L5OTHERCited in: Etiology and Triggering Factors - [40]
Spoială EL, Oltean C, Vasiliu I et al.. “Multimodal Management of Extreme Hypertriglyceridemia in a Child with Recurrent Pancreatitis: Clinical Challenges and Solutions.” Journal of clinical medicine (2026). PMID: 41598575 ↗
L5OTHERCited in: Etiology and Triggering Factors - [41]
Krajewska A, Tłustochowicz K, Kowalik A et al.. “Comparison of the Clinical Course, Management and Outcomes of Acute Pancreatitis in Aged and Young Patients.” Biomedicines (2026). PMID: 41595672 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, History and Physical Examination - [42]
Chiriac S, Sfarti C, Minea H et al.. “Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Bile Duct Stones-Avoiding the Avoidable.” Biomedicines (2026). PMID: 41595627 ↗
L5OTHERCited in: Etiology and Triggering Factors - [43]
Choudhary A, James A, Dahake U et al.. “Therapeutic plasmapheresis in a young infant with severe hypertriglyceridemia: a case report.” Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology (2026). PMID: 41923786 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [44]
Takasu S, Nakagawa M, Matsumoto S. “Autopsy case of a possible enigmatic triad accompanied by black esophagus and Wischnewsky spots.” Legal medicine (Tokyo, Japan) (2026). PMID: 41774981 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [45]
Vega J, Torres B, Maiz A et al.. “Case Report: Conventional therapy versus volanesorsen in two sisters with familial chylomicronemia syndrome.” Frontiers in nutrition (2026). PMID: 41737337 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Bodnar C, Hughey C, Bodker A et al.. “Milky Plasma, Murky Diagnosis: Urgent Plasma Exchange for Severe Hypertriglyceridemia-Induced Hyperviscosity Without Pancreatitis, but With Myocardial Infarction.” Journal of clinical apheresis (2026). PMID: 41709485 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Liu T, Cao Z, Lai F et al.. “Case Report: Vincristine-induced acute pancreatitis in pediatric Wilms tumor: first reported case challenging previous risk classifications and proposing vigilant monitoring protocols.” Frontiers in pediatrics (2025). PMID: 41602884 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [48]
Wang Z, Liu Y, Ren P et al.. “A prognostic model based on metabolic indicators for recurrent acute pancreatitis in hypertriglyceridemia patients: a retrospective cohort study.” Annals of medicine (2026). PMID: 41978916 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [49]
Gondal AN, Ahmed P, Akram F et al.. “Evaluation of Acute Pancreatitis in Patients Receiving Doxycycline Therapy: A Prospective Study.” Cureus (2026). PMID: 41646617 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [50]
Popa SL, Incze V, Ismaiel A et al.. “Non-Infectious Causes for Elevated Procalcitonin.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901546 ↗
L2aSR_OBSCited in: Pathophysiology - [51]
Yang X, Zhang L, Lin H et al.. “Early oral anti-inflammatory diet in patients with mild acute pancreatitis: study protocol for a randomized controlled trial.” Trials (2026). PMID: 41668182 ↗
L2bTRIAL_NONRANDOMCited in: Pathophysiology - [52]
Yan H, Dang X, Du G et al.. “IL-35, IL-37, and IL-38 in acute pancreatitis: proposed immunopathogenic mechanisms and therapeutic potential.” Frontiers in immunology (2026). PMID: 41737213 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Supportive Care and Complication Management - [53]
Tun HN, Rahal O, Figueroa Baez IR et al.. “Heart failure with preserved ejection fraction beyond the heart: exploring the heart-liver-pancreas axis.” ESC heart failure (2026). PMID: 41711215 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [54]
Zhang J, Chen H, Wang Y et al.. “Cell death and its interaction with mitochondrial dysfunction in pathogenesis of acute pancreatitis: a comprehensive review.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41663764 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [55]
Kurt SZE, Kurt E, Isin MS et al.. “The diagnostic value of the systemic immune-inflammation index in acute pancreatitis: a retrospective cohort study.” Irish journal of medical science (2026). PMID: 41926028 ↗
L2bCOHORTCited in: Pathophysiology - [56]
Ma H, Li N, Zhang H et al.. “The association between inflammatory indices and acute pancreatitis severity: a retrospective cohort study.” Frontiers in surgery (2026). PMID: 41835252 ↗
L2bCOHORTCited in: Pathophysiology - [57]
Chooklin S, Chuklin S. “Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.” Discover nano (2026). PMID: 41661463 ↗
L2aSR_OBSCited in: Pathophysiology - [58]
Wang Y, Ma L, Jiang Y et al.. “Revealing the temporal metabolic trajectory and potential pharmacodynamic substances of Da-Cheng-Qi Decoction in treating patients with acute pancreatitis: A serum metabolomics-based study.” Journal of ethnopharmacology (2026). PMID: 41825726 ↗
L1bRCTCited in: Pathophysiology - [59]
Alsaleh T, George J. “Targeted therapeutics for pancreatitis.” Frontiers in physiology (2026). PMID: 41907532 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [60]
Chooklin S, Chuklin S. “Beyond Supportive Care: Mitochondria as a Strategic Therapeutic Avenue in Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 41854947 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [61]
Chooklin S, Chuklin S. “Interleukin-22 in acute pancreatitis: Balancing damage and repair.” Hepatobiliary & pancreatic diseases international : HBPD INT (2026). PMID: 41763954 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [62]
Chooklin S, Chuklin S. “Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies.” Digestive diseases and sciences (2026). PMID: 41703270 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [63]
Dai NN, Geng ZG, Wang J et al.. “Pancreas-brain axis: exploring the pathogenic mechanisms of pancreatic encephalopathy.” International immunopharmacology (2026). PMID: 41689875 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [64]
Feng X, Lin J. “Advances in Glucocorticoid Therapy for Acute Pancreatitis: A Review.” Pancreas (2026). PMID: 41677367 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [65]
Xu K, Han Y, Chen F et al.. “Dose-dependent dissociation between intestinal protection and pancreatic outcome following licochalcone A treatment in severe acute pancreatitis.” Frontiers in pharmacology (2026). PMID: 41971086 ↗
L5OTHERCited in: Pathophysiology - [66]
Li H, Zhang X, He Z et al.. “Disruption of the Circadian Rhythm Induces Acute Pancreatitis via Amino Acid Metabolism-Mediated Macrophage Infiltration.” Cellular and molecular gastroenterology and hepatology (2026). PMID: 41903683 ↗
L5OTHERCited in: Pathophysiology - [67]
Guan L, Li X, He C et al.. “Bifidobacterium Pseudolongum-Derived Acetate Attenuates Acute Pancreatitis Through GPR43-Mediated Suppression of M1 Macrophage Polarization.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41903115 ↗
L5OTHERCited in: Pathophysiology - [68]
Uppal M, Neredimelli SK, Yadav HN et al.. “Development of an experimental model of severe acute pancreatitis with organ failure.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41881753 ↗
L5OTHERCited in: Pathophysiology, Supportive Care and Complication Management - [69]
Cheng L, Jiang C, Jiang W et al.. “Influences of probiotics plus enteral nutrition on intestinal flora and inflammatory response in patients with severe acute pancreatitis.” Frontiers in medicine (2026). PMID: 41877788 ↗
L5OTHERCited in: Pathophysiology - [70]
Joseph N, Kuhlmann L, Lucocq J et al.. “A Systematic Review of Pain Assessment Domains in Acute Pancreatitis Randomized Controlled Trials.” Pancreas (2026). PMID: 40748823 ↗
L1aSR_MA_RCTCited in: History and Physical Examination - [71]
Dobszai D, Obeidat M, Szalai EÁ et al.. “Metabolic syndrome components individually worsen the outcome of acute pancreatitis: a systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 41262260 ↗
L2aSR_OBSCited in: History and Physical Examination - [72]
Anderloni A, Spadaccini M, Binda C et al.. “Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial.” Gastroenterology (2026). PMID: 41511419 ↗
L1bRCTCited in: History and Physical Examination - [73]
Gan W, Zhang W, Cai J et al.. “A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG-ALL-2015.” Cancer medicine (2025). PMID: 40842042 ↗
L1bRCTCited in: History and Physical Examination - [74]
Han Y, Zhao H, Fu L et al.. “The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study.” Jornal de pediatria (2026). PMID: 41620210 ↗
L1bRCTCited in: History and Physical Examination - [75]
Wan J, Xiong S, Zou Y et al.. “Cumulative burden and dynamic trajectories of heart rate as predictors of prognosis in acute pancreatitis: an 18-year cohort study.” International journal of surgery (London, England) (2026). PMID: 40990508 ↗
L2bCOHORTCited in: History and Physical Examination - [76]
Kerbage A, Brunaldi VO, Al Annan K et al.. “Impact of Metabolic Surgery on the Severity and Outcomes of Acute Pancreatitis: A Retrospective Matched Cohort Study.” Obesity surgery (2025). PMID: 40804224 ↗
L2bCOHORTCited in: History and Physical Examination - [77]
Palermo TM, Ohls O, Dear B et al.. “Digital cognitive-behavioral therapy for pain management in individuals with recurrent acute and chronic pancreatitis (IMPACT-2): study protocol for a hybrid effectiveness-implementation trial.” Trials (2026). PMID: 41664170 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [78]
Jalleh RJ, Talley NJ, Horowitz M et al.. “The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.” The Journal of clinical investigation (2026). PMID: 41697736 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [79]
Tayier D, Wang K, Yuan Y et al.. “Research Status on the Effects of Obesity on Acute Pancreatitis.” Obesity reviews : an official journal of the International Association for the Study of Obesity (2026). PMID: 40751382 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [80]
Wang YX, Ge P, Chen HL. “Induction of hyperlipidemic pancreatitis by different fatty acids: A narrative review.” World journal of gastroenterology (2025). PMID: 40539203 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [81]
Zhu Q, Shan X, Tan D et al.. “Risk factor analysis and nomogram development for survival prediction in obese patients with severe acute pancreatitis: a retrospective study.” BMC gastroenterology (2025). PMID: 41013263 ↗
L2bCOHORTCited in: History and Physical Examination - [82]
Jaya Pragadeesh G, Abu Sali SA, Rajesh Kumar S et al.. “Gliptin induced acute pancreatitis: a literature review.” Acta gastro-enterologica Belgica (2025). PMID: 40504582 ↗
L2aSR_OBSCited in: History and Physical Examination - [83]
Mohamadnejad M, Hassanzadeh M, Anushirvani A et al.. “Immediate vs On-Demand Endoscopic Necrosectomy in Infected Walled-Off Pancreatic Necrosis: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41722664 ↗
L1bRCTCited in: Supportive Care and Complication Management - [84]
Eperjesi O, Bucur M, Rancz A et al.. “Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41807143 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [85]
Chooklin S, Chuklin S. “Neutrophil-to-lymphocyte ratio for primary risk stratification in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2025). PMID: 41608433 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [86]
Ren Y, Xia L, Luo L et al.. “Early direct admission to tertiary hospital specialized care reduces risk of severe acute pancreatitis: A propensity score-matched retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41692636 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [87]
Xu X, He C, Ding L et al.. “The similarity between microbiota of gut and pancreatic necrotic drainage fluid in infected pancreatic necrosis and its potential diagnostic value: a prospective observational cohort study.” BMC microbiology (2026). PMID: 41612182 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [88]
Shahzil M, Faisal MH, Khan MH et al.. “Comparative efficacy and safety of bi-flanged metal stents versus lumen-apposing metal stents for endoscopic drainage of pancreatic fluid collections: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41925047 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [89]
Shakeev K, Klyuyev D, Ogizbayeva A et al.. “Comparative Evaluation of the Prognostic Accuracy of IL-6 and Angiopoietin-2 for Early Severity Assessment in Acute Pancreatitis: A Systematic Review.” Diseases (Basel, Switzerland) (2026). PMID: 41590239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [90]
Qi R, Zhong J, Wang H et al.. “Nomogram for Predicting Pancreatic Pseudocyst in Hypertriglyceridemic Acute Pancreatitis: A Retrospective Cohort Study.” Journal of inflammation research (2026). PMID: 41982474 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [91]
Lew C, Jones M, Pham H et al.. “Outcomes of Patients With Severe Acute Pancreatitis Requiring Prolonged Intensive Care Admission at a Tertiary Centre: A Retrospective Cohort Study.” ANZ journal of surgery (2026). PMID: 41823127 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [92]
Cao Y, Li W, Peng P et al.. “Development and validation of an early prediction model for hypertriglyceridaemic severe acute pancreatitis: a retrospective study.” PeerJ (2026). PMID: 41584837 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [93]
Xu H, Zhang Z, Yang Y et al.. “Partial hepatectomy for pancreatic-origin hepatic abscess with intracystic hemorrhage following severe acute pancreatitis: a case report.” Frontiers in medicine (2026). PMID: 41868209 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [94]
Iacob A, Balan GG, Blaj M et al.. “Fungal Infections in Severe Acute Pancreatitis: Insights from a Case Series.” Journal of clinical medicine (2026). PMID: 41598727 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [95]
Tsuyama T, Suenaga S, Suehiro H et al.. “Lumen-apposing metal stent for peripancreatic fluid collection contributes to early improvement of nutritional status: A multicenter retrospective study (YCR-P001).” Medicine (2026). PMID: 41824843 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [96]
Zhang X, Peng K, Peng Y et al.. “Serum GAS6 is useful biomarker for identifying patients with severe acute pancreatitis within 24 h of admission: a multi-cohort analysis of 869 patients.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41956867 ↗
L5OTHERCited in: Supportive Care and Complication Management - [97]
Feng H, Wang P, He W et al.. “Development and interpretable machine learning models for classification of pancreatic pseudocyst risk in acute pancreatitis.” Frontiers in digital health (2026). PMID: 41924180 ↗
L5OTHERCited in: Supportive Care and Complication Management - [98]
Zhu P, Fang W, Tu H. “Development and validation of a nomogram model for predicting unplanned readmission in patients with acute pancreatitis.” Frontiers in endocrinology (2026). PMID: 41890191 ↗
L5OTHERCited in: Supportive Care and Complication Management - [99]
Lu H, Shen H, Cui J et al.. “Rhein attenuates severe acute pancreatitis-associated intestinal injury through PPARγ regulating macrophage activation.” Chinese medical journal (2026). PMID: 41859859 ↗
L5OTHERCited in: Supportive Care and Complication Management - [100]
Pauw HS, Schwarz R, Beij A et al.. “Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics.” The Journal of antimicrobial chemotherapy (2026). PMID: 41808660 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [101]
Kitagawa K, Asada S, Hanatani JI et al.. “Multi-Hole Self-Expandable Metallic Stent for Malignant Distal Biliary Obstruction: A Literature Review.” Journal of clinical medicine (2026). PMID: 41753098 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [102]
Fernandez Y Viesca M, Hadefi A, Otero Sanchez L et al.. “Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis.” Antibiotics (Basel, Switzerland) (2026). PMID: 41750517 ↗
L5OTHERCited in: Supportive Care and Complication Management - [103]
Yamashita Y, Kitano M. “EUS-guided pancreatic duct drainage-technical tips and outcomes: narrative review.” Therapeutic advances in gastroenterology (2026). PMID: 41732329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Ma S, Qin J, Luan J et al.. “Targeting mitochondrial phosphatase PGAM5 alleviates ferroptosis and acute pancreatitis by upregulating NRF2-mediated FSP1 expression.” Cell death & disease (2026). PMID: 41723122 ↗
L5OTHERCited in: Supportive Care and Complication Management - [105]
Siriwardena AK. “A Practical Guide to the Roles of Procalcitonin Measurement in Patients with Acute Pancreatitis.” Journal of clinical medicine (2026). PMID: 41682834 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [106]
Cárdenas-Jaén K, Guilabert L, Martínez-Moneo E et al.. “AEG-AESPANC-OPGE-SIED-SPG Ibero-Latin American Guidelines on Acute Pancreatitis (iLATAM-AP).” United European gastroenterology journal (2026). PMID: 42216617 ↗
L1aCited in: Definition, Synonyms, and Classification - [107]
Kudchadkar S, Peddakota V, Mudavath LC et al.. “Systematic Review of Role of Oxidative Stress and Clinical Implications in Acute Pancreatitis.” World journal of surgery (2026). PMID: 42438222 ↗
L2aCited in: Definition, Synonyms, and Classification - [108]
Wang F, Huang Z, Xue Z et al.. “APEX-NET: automated pancreatic evaluation network using early non-contrast CT.” European radiology (2026). PMID: 42377437 ↗
L2bCited in: Definition, Synonyms, and Classification - [109]
Madela F, Chiliza K, Mfeka X et al.. “Correlation between immune biomarkers and surrogate markers of severity of Acute Pancreatitis in an HIV endemic region.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 41314904 ↗
L2bCited in: Definition, Synonyms, and Classification - [110]
Hubert MO, Ahmad M, Crispin A et al.. “Meta-Analysis Obesity Correlates with Severity and Mortality in Acute Pancreatitis: An Updated Meta-Analysis.” Digestive diseases (Basel, Switzerland) (2026). PMID: 42139165 ↗
L2aCited in: Definition, Synonyms, and Classification - [111]
Rantsev M, Sarapultsev A, Chereshnev V. “Neuromodulatory Interventions in Experimental Acute Pancreatitis: A Systematic Review of Rodent Studies.” Diseases (Basel, Switzerland) (2026). PMID: 42041637 ↗
L2aCited in: Definition, Synonyms, and Classification - [112]
Yavuz A, Ebik B, Karabulut Ü et al.. “Evaluation of the Admission Neutrophil Percentage-to-Albumin Ratio for Predicting the Severity of Acute Pancreatitis.” Biomedicines (2026). PMID: 42512016 ↗
L3bCited in: Definition, Synonyms, and Classification - [113]
Yu M, Mao E, Xu Y et al.. “Triglyceride Threshold for Intensive Lipid-Lowering Therapy in Acute Hyper-Triglyceridemic Pancreatitis: A Retrospective Study.” Journal of clinical medicine (2026). PMID: 42355749 ↗
L3bCited in: Definition, Synonyms, and Classification - [114]
Wei W, Wang Y, Xie P et al.. “Development of a prediction method for severe pancreatitis using a nomogram.” Frontiers in medicine (2026). PMID: 42180752 ↗
L3bCited in: Definition, Synonyms, and Classification - [115]
Chiarello MM, Fico V, Misuriello F et al.. “Are BISAP and APACHE II scores still useful to identify high-risk patients in acute pancreatitis? A retrospective multicenter analysis on 450 patients.” Updates in surgery (2026). PMID: 42166093 ↗
L3bCited in: Definition, Synonyms, and Classification - [116]
Hao X, Feng X, Liu F et al.. “Real-time guidance of lauromacrogol ablation for pancreatic cystic lesions using confocal laser endomicroscopy.” Therapeutic advances in gastroenterology (2026). PMID: 41705165 ↗
L3bCited in: Definition, Synonyms, and Classification - [117]
Xu X, Xu T, Wang Y et al.. “Clinical value of BISAP score combined with low-density lipoprotein cholesterol and ascites in early prediction of hypertriglyceridemic severe acute pancreatitis.” Frontiers in endocrinology (2025). PMID: 41446633 ↗
L3bCited in: Definition, Synonyms, and Classification - [118]
Saullo P, Caronna R, Angelici AM et al.. “Value of Continuous Hemofiltration in Patients with Severe Acute Pancreatitis at Onset: Single Centre Experience on 48 Patients.” Journal of clinical medicine (2025). PMID: 41010851 ↗
L3bCited in: Definition, Synonyms, and Classification - [119]
Masson W, Lobo M, Mansur M et al.. “Clinical effects of apolipoprotein C3 inhibitors on triglyceride levels and pancreatitis risk: a systematic review and meta-analysis.” Minerva endocrinology (2026). PMID: 42329673 ↗
L1aCited in: Etiology and Triggering Factors - [120]
Liang AC, Castillo YC, Bruciaga LMM et al.. “Comparative Efficacy of Insulin and Alternative Therapies for Hypertriglyceridemia-Associated Acute Pancreatitis: A Systematic Review and Network Meta-Analysis.” Digestive diseases and sciences (2026). PMID: 42301369 ↗
L1aCited in: Etiology and Triggering Factors - [121]
Gad MM, Ayad Q, Elgamal MM et al.. “Cholecystectomy versus conservative management for patients with uncomplicated symptomatic gallstones and cholecystitis: an updated systematic review and meta-analysis.” BMC surgery (2026). PMID: 42265664 ↗
L1aCited in: Etiology and Triggering Factors - [122]
Shen Y, Bai Y. “Rectal Nonsteroidal Anti-Inflammatory Drugs, Aggressive Hydration With Lactated Ringer's Solution, Somatostatin or Combinations for Prophylaxis Post-ERCP Acute Pancreatitis: A Network Meta-Analysis.” Pancreas (2026). PMID: 42240446 ↗
L1aCited in: Etiology and Triggering Factors - [123]
Soran H, Kessler AS, Vera-Llonch M et al.. “Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.” Journal of comparative effectiveness research (2026). PMID: 42319369 ↗
L1bCited in: Etiology and Triggering Factors - [124]
Tarar ZI, Gandhi M, Farooq U et al.. “Prophylactic biliary stenting post-ERCP prior to cholecystectomy: a systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42443680 ↗
L2aCited in: Etiology and Triggering Factors - [125]
Shaaban Abdelgalil M, Abdelrazek A, Mohamed MS et al.. “EUS-guided hepaticogastrostomy versus EUS-guided hepaticogastrostomy with antegrade stent placement in patients with unresectable malignant distal biliary obstruction: a meta-analysis of individual patient data.” BMC gastroenterology (2026). PMID: 42436411 ↗
L2aCited in: Etiology and Triggering Factors - [126]
Liu J, Yu Y, Qiu X et al.. “Baseline current smoking and time-varying recurrence risk after first-episode of hypertriglyceridemia-induced acute pancreatitis: A multicenter retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42570923 ↗
L3bCited in: Etiology and Triggering Factors - [127]
Li J, Liu X, Zhao R et al.. “Analysis of the association between the neutrophil-to-lymphocyte ratio (NLR) and liver injury complicating acute pancreatitis: a retrospective study.” Frontiers in medicine (2026). PMID: 42559316 ↗
L3bCited in: Etiology and Triggering Factors - [128]
Ain Q, Huda NU, Khan M et al.. “Prevalence and clinical characteristics of probable familial chylomicronaemia syndrome at a tertiary care center in Pakistan: Insights from a hospital-based screening study.” Journal of clinical lipidology (2026). PMID: 42538190 ↗
L3bCited in: Etiology and Triggering Factors - [129]
Uemura S, Iwashita T, Koizumi T et al.. “Visceral Adipose Tissue as an Independent Predictor of Severe Post-ERCP Pancreatitis: A Multicenter Retrospective Cohort Study.” Journal of hepato-biliary-pancreatic sciences (2026). PMID: 42494284 ↗
L3bCited in: Etiology and Triggering Factors - [130]
Yang S, Li C, Zeng K et al.. “Development and validation of a 24-h predictive model for hypertriglyceridemic moderately severe acute pancreatitis: a single-center retrospective study.” Frontiers in medicine (2026). PMID: 42465082 ↗
L3bCited in: Etiology and Triggering Factors - [131]
Selin D, Oskarsson V, Maret-Ouda J et al.. “Cholecystectomy vs Endoscopic Retrograde Cholangiopancreatography or No Intervention After Gallstone-Related Acute Pancreatitis.” JAMA surgery (2026). PMID: 42340741 ↗
L3bCited in: Etiology and Triggering Factors - [132]
Guo Q, Chen W, Qin K et al.. “Integrating 2.5D multi-modal CT imaging with serum triglycerides for early risk stratification in hypertriglyceridemia-induced acute pancreatitis: A multicenter study.” European journal of radiology (2026). PMID: 42322722 ↗
L3bCited in: Etiology and Triggering Factors - [133]
Liu Z, Li Z, Liu D et al.. “Clinical outcomes of immediate, 24-h, and 24-72-h laparoscopic cholecystectomy after endoscopic stone clearance: a matched cohort analysis.” Surgical endoscopy (2026). PMID: 42257960 ↗
L3bCited in: Etiology and Triggering Factors - [134]
Liu F, Liu XQ, Gu DJ et al.. “Laparoscopic common bile duct exploration and primary suture versus ERCP combined with laparoscopic cholecystectomy for choledocholithiasis: a retrospective comparative study.” Surgical endoscopy (2026). PMID: 42257936 ↗
L3bCited in: Etiology and Triggering Factors - [135]
An J, Zhang G, Zhou X. “A prognostic model based on integrated clinical indicators for recurrent acute pancreatitis in patients with hypertriglyceridemia: a retrospective cohort study.” Lipids in health and disease (2026). PMID: 42249448 ↗
L3bCited in: Etiology and Triggering Factors - [136]
Yao W, Zhao C, Cao L et al.. “Development and Validation of an Early Severity Prediction Model for Hypertriglyceridemia-Associated Acute Pancreatitis: A Multicenter Cohort Study.” Journal of inflammation research (2026). PMID: 42375817 ↗
L2bCited in: Etiology and Triggering Factors - [137]
Zhao G, Wang Y, Zhang G et al.. “Risk factors for post-ERCP pancreatitis and assessment of stent exchange intervals in children with chronic pancreatitis: a single-center retrospective study.” BMC pediatrics (2026). PMID: 42343307 ↗
L2bCited in: Etiology and Triggering Factors - [138]
Nishimura M, Miwa H, Kaneko T et al.. “Post-Endoscopic Retrograde Cholangiopancreatography Bleeding After Endoscopic Stone Removal in Dialysis Patients: A Multicenter Retrospective Study.” DEN open (2026). PMID: 42569438 ↗
L4Cited in: Etiology and Triggering Factors - [139]
Wang L, Nie Z, Huang Q. “Effect of a structured early rehabilitation program on long-term functional recovery, quality of life, and survival in patients with severe acute pancreatitis: a randomized controlled trial.” BMC gastroenterology (2026). PMID: 42204448 ↗
L1bCited in: Pathophysiology - [140]
Tian H, Wang L, He Z et al.. “Global landscape and knowledge structure of research on pancreatitis and gut microbiota: a bibliometric analysis based on WoSCC and Scopus (2006 - 2025).” Frontiers in cellular and infection microbiology (2026). PMID: 42568357 ↗
L2aCited in: Pathophysiology - [141]
Pakai E, Klonfar K, Walter A et al.. “Fever on hospital admission is associated with increased disease severity and mortality in acute pancreatitis: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 42482129 ↗
L2aCited in: Pathophysiology - [142]
Naz F, Qaiser F, Mumtaz A et al.. “Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.” Medicine (2026). PMID: 42536519 ↗
L1aCited in: Pathophysiology - [143]
Sang H, Liu X, Song J. “Visceral adipose tissue and acute pancreatitis: a systematic review and meta-analysis.” PeerJ (2026). PMID: 42254660 ↗
L2aCited in: Pathophysiology - [144]
Ben Ismail I, Sghaier M, Zenaidi H et al.. “The Neutrophil-Creatinine Index as an Early Predictor of Severe Acute Pancreatitis.” The Journal of surgical research (2026). PMID: 42556197 ↗
L3bCited in: Pathophysiology - [145]
Pădureanu V, Florescu DN, Cazacu SM et al.. “Evaluation of oxidative stress in acute pancreatitis.” Frontiers in immunology (2026). PMID: 42220490 ↗
L3bCited in: Pathophysiology - [146]
Huang A, Yuan Q, Chen J et al.. “Deep chemical structure graph learning deciphers the lipotoxicity code of hypertriglyceridemic pancreatitis.” NPJ digital medicine (2026). PMID: 42204286 ↗
L3bCited in: Pathophysiology - [147]
Gu H, Tang C, Shi Y et al.. “sEV-Enriched Serum Preparations From Healthy Individuals Protect Against Acute Pancreatitis-Induced Intestinal Barrier Dysfunction Through miR-579-3p/ANXA3-Mediated Inhibition of NLRP3 Inflammasome Pyroptosis.” Archivum immunologiae et therapiae experimentalis (2026). PMID: 42347491 ↗
L3bCited in: Pathophysiology - [148]
Chen X, Li Z, Mao T et al.. “Predictive value of sarcopenia-related clinical indices for early disease progression in acute pancreatitis: a multicenter retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42564036 ↗
L3bCited in: Pathophysiology - [149]
Wen Y, Chen W, Zhang W et al.. “The Correlation Analysis of C-Reactive Protein-Triglyceride-Glucose Index with the Severity of Hyperlipidemic Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 42474624 ↗
L3bCited in: Pathophysiology - [150]
Wang Z, Liu Y, Li C. “Nutritional modulation of disease severity in acute pancreatitis: metabolic pathways, inflammatory signaling, and diet-responsive clinical outcomes.” Frontiers in nutrition (2026). PMID: 42459810 ↗
L3bCited in: Pathophysiology - [151]
Yu W, Yang P, Ding M et al.. “Acute pancreatitis temporally associated with COVID-19 pneumonia in a patient with post-tuberculosis chronic pulmonary aspergillosis: a case report.” Frontiers in medicine (2026). PMID: 42344497 ↗
L4Cited in: Pathophysiology - [152]
Ambli S, Gupta BK, Pandey AR et al.. “Comparison of the incidence of acute kidney injury in patients with acute pancreatitis managed with or without thoracic epidural analgesia: A prospective randomized controlled trial.” International journal of critical illness and injury science (2026). PMID: 42281814 ↗
L1bCited in: Pathophysiology - [153]
Turkmen B, Özel Yetkin M, Yenişekerci Kulak E et al.. “The Global Immune-Nutrition-Inflammation Index (GINI) in Acute Pancreatitis Severity Assessment: A Comparative Study.” Digestive diseases and sciences (2026). PMID: 42570998 ↗
L3bCited in: Pathophysiology - [154]
Cohen BD, Eluri N, Levine S et al.. “Atrial fibrillation and cardiovascular comorbidity burden as predictors of in-hospital mortality in acute pancreatitis: A National Inpatient Sample analysis of 1.9 million hospitalizations.” International journal of cardiology. Cardiovascular risk and prevention (2026). PMID: 42382912 ↗
L3bCited in: Pathophysiology - [155]
Mareninova OA, Chang AG, Hernandez Malpica S et al.. “Genetic and pharmacologic modulations elucidate NRF2 protective role in acute pancreatitis.” American journal of physiology. Gastrointestinal and liver physiology (2026). PMID: 42530545 ↗
L5Cited in: Pathophysiology - [156]
Pandanaboyana S, Knoph CS, Kuhlmann L et al.. “European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations.” United European gastroenterology journal (2026). PMID: 42299777 ↗
L1cCited in: History and Physical Examination - [157]
Hammad N, Ramadan AM, Nazmy A et al.. “Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.” Diabetes technology & therapeutics (2026). PMID: 41640110 ↗
L1aCited in: History and Physical Examination - [158]
Aguilar-Salinas CA, Alonso R, Berg G et al.. “A multi-society Delphi consensus statement on the diagnosis of familial chylomicronemia syndrome.” Archives of endocrinology and metabolism (2025). PMID: 41026863 ↗
L1cCited in: History and Physical Examination - [159]
Liu Y, Feng XY, Chen C et al.. “Nutritional recovery after minimally invasive pancreatic stone treatment: Body mass index dynamics and predictors in chronic pancreatitis cohorts.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 42108155 ↗
L2bCited in: History and Physical Examination - [160]
López FV, Kesavan P, Win LK et al.. “Hyperamylasaemia in paediatric inflammatory bowel disease: Aetiology, outcomes and genetic determinants.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42037072 ↗
L4Cited in: History and Physical Examination - [161]
Kuhlmann L, Davidsen L, Knoph CS et al.. “Trajectories of Pain Processing in Recurrent Acute and Chronic Pancreatitis: A Longitudinal Quantitative Sensory Testing Study.” European journal of pain (London, England) (2026). PMID: 41842672 ↗
L4Cited in: History and Physical Examination - [162]
Gao L, Zhang R, Xiao Y et al.. “High Serum Lipase Level is Associated With Increased Analgesic Use in Hospitalized Patients With Acute Pancreatitis.” Pain research & management (2026). PMID: 41808845 ↗
L3bCited in: History and Physical Examination - [163]
Tartaglia E, Bucci T, Rossi M et al.. “Risk of all-cause death and pancreatic events following GLP-1 RA initiation in people with obesity or type 2 diabetes: observations from a federated research network.” Cardiovascular diabetology (2025). PMID: 41257737 ↗
L3bCited in: History and Physical Examination - [164]
Gu RJ, Zhang YR. “Predictive utility of the triglyceride-glucose index and visceral adiposity-related indices for severe progression in hypertriglyceridemic pancreatitis.” Journal of clinical lipidology (2025). PMID: 41162245 ↗
L3bCited in: History and Physical Examination - [165]
Tarján D, Szalai EÁ, Erőss B et al.. “Safety and Effectiveness of Cholecystectomy and Endoscopic Retrograde Cholangiopancreatography in Biliary Pancreatitis During Pregnancy: BORN Study.” United European gastroenterology journal (2025). PMID: 41045491 ↗
L4Cited in: History and Physical Examination - [166]
Zhou AL, Chiang JY, Chan KS et al.. “Decoding Alexander the Great's gastrointestinal cause of death using artificial wisdom: An artificial intelligence-human inquiry into a medical mystery.” World journal of gastroenterology (2025). PMID: 41479650 ↗
L3bCited in: History and Physical Examination - [167]
Barbar M, Kanaan D, AlZebin Z et al.. “Severe asparaginase-associated hypertriglyceridemia in pediatric acute lymphoblastic leukemia: a single-center experience.” Frontiers in oncology (2026). PMID: 42415868 ↗
L4Cited in: History and Physical Examination - [168]
Yu B, Li Y, Li N et al.. “Age-related vulnerability and clinical outcomes in acute pancreatitis: a stratified cohort study of 1,034 patients.” BMC gastroenterology (2026). PMID: 42304224 ↗
L3bCited in: History and Physical Examination - [169]
Cui N, Wang W, Xu W. “Therapeutic Outcomes and Risks of Plasmapheresis in Hypertriglyceridemia Acute Pancreatitis: A Systematic Review and Meta-analysis.” Digestion (2026). PMID: 42647439 ↗
L1aCited in: Etiology and Triggering Factors - [170]
Yao Y, Yuan B, Wang K et al.. “An explainable machine learning framework integrating clinical and lipidomic signatures for early severity stratification of hypertriglyceridemic pancreatitis.” Frontiers in medicine (2026). PMID: 42638867 ↗
L2bCited in: Etiology and Triggering Factors - [171]
Warfield MN, Cole KC, Heybati K et al.. “Safety of Coadministration of Continuous Infusions of Propofol and Clevidipine: A Multi-Site Retrospective Analysis.” Pharmacotherapy (2026). PMID: 42666011 ↗
L4Cited in: Etiology and Triggering Factors - [172]
Paquette M, Guay SP, Baass A. “Validation of two familial chylomicronemia syndrome clinical diagnosis scores in a cohort of molecularly defined patients.” Journal of clinical lipidology (2026). PMID: 42637648 ↗
L3bCited in: Etiology and Triggering Factors - [173]
Li Y, Wan X, Wang Y et al.. “Combining MRI dual-sequence radiomics and clinical parameters predicts post-hypertriglyceridemic acute pancreatitis diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42609407 ↗
L3bCited in: Etiology and Triggering Factors - [174]
Zhu K, Lu B, Zhou R et al.. “Lactate Dehydrogenase, Interleukin-6, and 24 h Intra-Abdominal Pressure Exhibit Early Predictive Value in Hypertriglyceridemic Pancreatitis Complicated by Acute Respiratory Distress Syndrome.” Emergency medicine international (2026). PMID: 42688871 ↗
L3bCited in: Etiology and Triggering Factors - [175]
Ahmed K, Ismail A, Elawad A et al.. “Prior bariatric surgery and better short-term outcomes in acute pancreatitis: a multicenter propensity-matched analysis.” Annals of gastroenterology (2026). PMID: 42434159 ↗
L3bCited in: Etiology and Triggering Factors - [176]
Xiang D, Yuan L, Liao S et al.. “A case report of young-onset type 2 diabetes patient with severe metabolic dysregulation carrying an LRP6 variant.” Frontiers in endocrinology (2026). PMID: 42723884 ↗
L4Cited in: Etiology and Triggering Factors - [177]
Liu M, Wu D, Su C. “Insulin is central, plasmapheresis is salvage: clinical spectrum and management of severe hypertriglyceridemia in 21 children with diabetic ketoacidosis.” Frontiers in endocrinology (2026). PMID: 42718762 ↗
L4Cited in: Etiology and Triggering Factors - [178]
Chen X, Zhou L, Huang Y et al.. “Hemoperfusion with Hemodiafiltration Versus Standard Medical Therapy for Severe Acute Pancreatitis: A Retrospective Study.” Digestive diseases and sciences (2026). PMID: 42702672 ↗
L1bCited in: Pathophysiology - [179]
Farrell PR, Lee B, Ahmed F et al.. “TRANCE is a unique marker of chronic pancreatitis in children.” JCI insight (2026). PMID: 42635043 ↗
L2bCited in: Pathophysiology - [180]
Ye HW, Liu F, Gu DJ et al.. “Impact of acute cholangitis severity on the safety of laparoscopic common bile duct exploration with primary closure: a stratified retrospective study.” Surgical endoscopy (2026). PMID: 42680926 ↗
L3bCited in: Pathophysiology - [181]
Vazzana GF, Romano A, Romano C. “Idiopathic Acute Pancreatitis in Paediatric Inflammatory Bowel Disease: Clinical Features and Outcomes in a Retrospective Single-Centre Study.” Journal of paediatrics and child health (2026). PMID: 42625467 ↗
L4Cited in: Pathophysiology - [182]
Kosidło JW, Dorf J, Kamińska J et al.. “Unveiling the multidimensional cytokine landscape in acute pancreatitis.” Frontiers in immunology (2026). PMID: 42643960 ↗
L3bCited in: Pathophysiology - [183]
Obeidat A, Sallam A, Chang C. “Clinical and in-hospital outcomes of alcohol-related pancreatitis in the setting of concomitant alcohol-related hepatitis: A retrospective cohort study.” The American journal of the medical sciences (2026). PMID: 42580663 ↗
L3bCited in: Pathophysiology - [184]
Chen C, Zhao Y, Lin X et al.. “Case Report: A rare case of concurrent diabetic ketoacidosis and severe acute pancreatitis, followed by Guillain-Barré syndrome and Wernicke's encephalopathy.” Frontiers in endocrinology (2026). PMID: 42718484 ↗
L4Cited in: Pathophysiology - [185]
Mititelu A, Grama A, Bența G et al.. “Acute and Recurrent Pancreatitis in Children: Insights into Etiology and Clinical Course from a Retrospective Single-Center Study.” Children (Basel, Switzerland) (2026). PMID: 42650422 ↗
L3bCited in: History and Physical Examination - [186]
Bhattarai S, Baral S, Bhowmick M et al.. “Short-Term Changes in Body Composition and the Development of Sarcopenia Following Acute Pancreatitis: An Observational Study.” Digestive diseases and sciences (2026). PMID: 42223541 ↗
L3bCited in: History and Physical Examination - [187]
Agaoglu Z, Toptas GR, Serbetci H et al.. “Evaluation of Maternal and Fetal Outcomes in Pregnant Women with Acute Pancreatitis: A Five-Year Retrospective Study from a Tertiary Center.” Digestive diseases and sciences (2026). PMID: 42154121 ↗
L3bCited in: History and Physical Examination - [188]
Roberts KM, Thongkhao-On S, Culp S et al.. “Dietary Patterns Following an Episode of Acute Pancreatitis: A Post Hoc Analysis From the PAPPEI Multicenter, Prospective Study.” Pancreas (2026). PMID: 42047302 ↗
L3bCited in: History and Physical Examination - [189]
Chen SC, Liu KW, Huang YN et al.. “Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.” American journal of therapeutics (2026). PMID: 41992281 ↗
L3bCited in: History and Physical Examination - [190]
Chleirigh NN, O'Broin ER, Shet S et al.. “10 year cumulative diagnostic radiation exposure after acute pancreatitis: a retrospective comparison of acute interstitial oedematous and necrotising pancreatitis.” BMC gastroenterology (2026). PMID: 41888675 ↗
L4Cited in: History and Physical Examination - [191]
Calabrese EC, Shehata D, Slater BJ et al.. “SAGES clinical practice guidelines for the management of symptomatic walled-off pancreatic necrosis.” Surgical endoscopy (2026). PMID: 42675307 ↗
L1cCited in: Supportive Care and Complication Management - [192]
Fang Y, Chen X, Cai L et al.. “Comparative efficacy and safety of Xuesaitong injection as adjuvant therapy for acute pancreatitis: a systematic review and meta-analysis.” Frontiers in pharmacology (2026). PMID: 42591735 ↗
L1aCited in: Supportive Care and Complication Management - [193]
Jiang W, Peng J, Wu Q et al.. “Normal saline vs. lactated ringer's for fluid resuscitation in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42180723 ↗
L1aCited in: Supportive Care and Complication Management - [194]
Ding L, Wang Z, Wang Y et al.. “Hypertriglyceridemic pancreatitis subphenotypes and differential responses to low-molecular-weight heparin: analyses from a cohort and a randomized controlled trial.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 42420072 ↗
L1bCited in: Supportive Care and Complication Management - [195]
Wu Y, Gao Y, Fang Z et al.. “Time-dependent microbiology of peripancreatic drainage fluid in severe acute pancreatitis: a prospective real-world observational study using metagenomic sequencing and culture.” Frontiers in medicine (2026). PMID: 42328576 ↗
L2bCited in: Supportive Care and Complication Management - [196]
Chen X, Su L, Zhang D et al.. “Association between peak D-dimer levels within 24 hours of admission and the risk of infected pancreatic necrosis in hyperlipidemic acute pancreatitis: a retrospective analysis.” Frontiers in medicine (2026). PMID: 42712372 ↗
L3bCited in: Supportive Care and Complication Management - [197]
Zuo Q, Cui M, Li J et al.. “Robot-assisted pancreatic necrosectomy for infected pancreatic necrosis secondary to severe acute pancreatitis: a single-center retrospective cohort study.” Journal of robotic surgery (2026). PMID: 42671732 ↗
L3bCited in: Supportive Care and Complication Management - [198]
Ouyang S, Fan Y, Liu F et al.. “Automated CT Volumetry of Peripancreatic Collections for Risk Stratification in Acute Pancreatitis: A Multicenter Retrospective Study.” Academic radiology (2026). PMID: 42567794 ↗
L3bCited in: Supportive Care and Complication Management - [199]
Anandalwar SP, Clark J, Vesselinov R et al.. “Does the risk outweigh the benefit? Clot progression, recanalization & complications of anticoagulation therapy in acute pancreatitis with concomitant splanchnic vein thrombosis.” American journal of surgery (2026). PMID: 42398215 ↗
L3bCited in: Supportive Care and Complication Management - [200]
Zhang H, Chen D, Tian H et al.. “Perioperative nursing management in video-assisted retroperitoneal debridement for severe acute pancreatitis with infected peripancreatic necrosis: a retrospective single-center case series of 41 patients.” Frontiers in surgery (2026). PMID: 42369635 ↗
L4Cited in: Supportive Care and Complication Management - [201]
Zhang JX, Jin HS, Lu SS et al.. “Potential benefit of mirabilite external dressing combined with abdominal drainage in the early stage of severe acute pancreatitis.” BMC gastroenterology (2026). PMID: 42426625 ↗
L2bCited in: Supportive Care and Complication Management - [202]
Hayashi H, Kubo T, Hara T et al.. “Non-keratinizing immature squamous metaplasia in the pancreas mimicking malignancy: a diagnostic pitfall in cytology.” Journal of pathology and translational medicine (2026). PMID: 42452874 ↗
L3bCited in: Supportive Care and Complication Management - [203]
Lan L, Cheng G, He M et al.. “Fluid resuscitation in the early management of acute pancreatitis: a five-year retrospective observational study.” World journal of emergency medicine (2026). PMID: 42199765 ↗
L3bCited in: Supportive Care and Complication Management - [204]
Grover AS, Reiss DE, Templeton K et al.. “Endoscopic ultrasound-guided drainage of pancreatic fluid collections is safe to perform in children: A comparison of two endoscopic approaches.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42626823 ↗
L4Cited in: Supportive Care and Complication Management - [205]
Li M, Fu Y, Chen Y et al.. “Case Report: Early documented infected pancreatic necrosis due to carbapenem-resistant Acinetobacter baumannii and concurrent Enterococcus faecium bacteremia: a salvage regimen with sulbactam-durlobactam and tigecycline.” Frontiers in medicine (2026). PMID: 42440864 ↗
L4Cited in: Supportive Care and Complication Management - [206]
Jacq E, Maire F, Cucherousset J et al.. “From Cutaneous Necrosis to Septic Shock: An ICU Case of Pancreatico portal Fistula Complicating Necrotizing Acute Pancreatitis.” Critical care explorations (2026). PMID: 42390290 ↗
L4Cited in: Supportive Care and Complication Management - [207]
Zhang H, Li S, Feng Y et al.. “Evaluating the efficacy of intensified insulin therapy in hypertriglyceridemic acute pancreatitis management: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42824056 ↗
L1aCited in: Etiology and Triggering Factors - [208]
Pan J, Peng W, Wu M et al.. “Clinical characteristics, management, and outcome of tamoxifen-induced hyperlipidemia: a systematic review.” Frontiers in pharmacology (2026). PMID: 42824100 ↗
L4Cited in: Etiology and Triggering Factors - [209]
Ma G, Lu C, Xiang H et al.. “Multisystem laboratory changes before and after blood purification in acute pancreatitis: a real-world descriptive analysis of 141 cases.” Frontiers in medicine (2026). PMID: 42846549 ↗
L3bCited in: Etiology and Triggering Factors - [210]
Cui J, Li J, Sun Z et al.. “Early in-hospital triglyceride clearance trajectories and time-weighted mean exposure in hypertriglyceridemia-associated acute pancreatitis: associations with disease severity and pancreatic necrosis.” Frontiers in medicine (2026). PMID: 42780899 ↗
L3bCited in: Etiology and Triggering Factors - [211]
Oduru O, Rahman AF, Baig Kr KK et al.. “Children with sickle cell disease hospitalized for acute pancreatitis have an increased disease burden.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42768945 ↗
L3bCited in: Etiology and Triggering Factors - [212]
Baumgartner EE, Weltin L, Wurster J et al.. “Outcomes of Early Versus Delayed ERCP in Gallstone Pancreatitis, Stratified by BISAP Severity.” Clinics and research in hepatology and gastroenterology (2026). PMID: 42892534 ↗
L4Cited in: Etiology and Triggering Factors - [213]
Dai J, Xiao Y, Han Y et al.. “Single-session therapeutic plasma exchange as salvage therapy for pegaspargase-induced severe acute pancreatitis accompanied by multiple organ dysfunction in a pediatric patient with B-cell precursor acute lymphoblastic leukemia: a case report.” BMC pediatrics (2026). PMID: 42823759 ↗
L2bCited in: Etiology and Triggering Factors - [214]
Angelescu C, Bădărău IA, Mateescu RB. “Clinical Characteristics, ERCP Management, and Early Adverse Events Among Patients with Choledocholithiasis at a Romanian Tertiary Referral Center: A Retrospective Cohort.” Diseases (Basel, Switzerland) (2026). PMID: 42783233 ↗
L4Cited in: Etiology and Triggering Factors - [215]
Yeşilyurt S, Şentürk A, Demirtakan T et al.. “Comparative Prognostic Performance of Inflammatory and Immunonutritional Indices in Acute Pancreatitis: A Head-to-Head Cohort Study.” Journal of clinical medicine (2026). PMID: 42881954 ↗
L2bCited in: Pathophysiology - [216]
Damar Ö, Yaman M. “Incremental Prognostic Value of the Admission Systemic Immune-Inflammation Index Beyond BISAP for Early Risk Stratification of Acute Pancreatitis in the Emergency Department.” Journal of clinical medicine (2026). PMID: 42739593 ↗
L2bCited in: Pathophysiology - [217]
Wang J, Chen S, Zhao X et al.. “A clinical study on the application of new inflammatory markers SII, SIRI, AISI, and MII in the identification of severe acute pancreatitis.” Frontiers in medicine (2026). PMID: 42846429 ↗
L3bCited in: Pathophysiology - [218]
Tesseraux AM, Howard J, Peters LM. “Low plasma butyrylcholinesterase activity in dogs: prevalence, association with underlying disorders, laboratory variables, and survival.” Journal of veterinary internal medicine (2026). PMID: 42842763 ↗
L3bCited in: Pathophysiology - [219]
Xu T, Gao Y, Zhang Z et al.. “C-reactive protein-triglyceride-glucose index predicts acute pancreatitis severity: a retrospective cross-sectional study.” Frontiers in endocrinology (2026). PMID: 42835067 ↗
L3bCited in: Pathophysiology - [220]
Gao Q, Li C, Liu J et al.. “miR-215-5p aggravates severe acute pancreatitis by inhibiting SLC7A11 to induce ferroptosis.” BMC gastroenterology (2026). PMID: 42773417 ↗
L3bCited in: Pathophysiology - [221]
Rao L, Zhou W, Zhong B et al.. “Impact of early enteral nutrition on children with acute pancreatitis: A systematic review and meta analysis.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 42736108 ↗
L1aCited in: Supportive Care and Complication Management - [222]
He T, Zhang Y, Wen X et al.. “Procalcitonin for diagnosing infected pancreatic necrosis: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 42881372 ↗
L1aCited in: Supportive Care and Complication Management - [223]
Wu B, Wei W, Zhang K et al.. “Pancreatic microbiota composition and diversity in pancreatitis-associated infection: a systematic review with focus on infected pancreatic necrosis.” Frontiers in microbiology (2026). PMID: 42824567 ↗
L2aCited in: Supportive Care and Complication Management - [224]
Sun J, Zheng J, Shen Y. “Safety and efficacy of microbiota-directed adjunctive therapy in acute pancreatitis: a systematic review and meta-analysis of prebiotics, probiotics, and synbiotics.” Frontiers in medicine (2026). PMID: 42798434 ↗
L2aCited in: Supportive Care and Complication Management - [225]
Asavachaisuvikom A, Tangtawee P, Rungsakulkij N et al.. “Impact of postoperative hyperamylasemia and post-pancreatectomy acute pancreatitis following pancreaticoduodenectomy in a single-center cohort.” Gland surgery (2026). PMID: 42866823 ↗
L3bCited in: Supportive Care and Complication Management - [226]
Sun Y, Liu B, Loh H et al.. “Glucagon-like Peptide-1 Receptor Agonists Are Not Associated with Increased Risk of Acute Pancreatitis or Pancreatic Complications, Including Pancreatic Cancer, in Type 2 Diabetes: A Global Propensity-Matched Cohort Study.” Journal of personalized medicine (2026). PMID: 42783509 ↗
L3bCited in: Supportive Care and Complication Management - [227]
Toussaint N, Marichez A, Boubaddi M et al.. “Preoperative biliary drainage in resectable perihilar cholangiocarcinoma: real-world burden.” Expert review of gastroenterology & hepatology (2026). PMID: 42775491 ↗
L3bCited in: Supportive Care and Complication Management